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Mucoepidermoid carcinoma (MEC) is a life-threatening salivary gland cancer for 
which treatment options and targeted therapies are lacking. This tumor type is 
frequently characterized by a recurrent t(11;19)(q21;p13) chromosomal translocation 
which generates the transcriptional coactivator fusion CRTC1/MAML2. While it is clear 
that CRTC1/MAML2 plays a key role in maintaining a transformed state in MEC, the 
mechanisms by which this fusion oncogene rewires gene expression programs that 
promote tumorigenesis remain poorly understood. Here, we show that CRTC1/MAML2 
induces transcriptional activation of a non-canonical PGC-1α splice variant, PGC-1α4, 
which regulates PPARγ-dependent expression of the IGF-1 growth hormone. This 
dependence on autocrine regulation of IGF-1 transcription via PGC-1α4/PPARγ renders 
MEC cells susceptible to IGF-1R inhibition with small molecules and to PPARγ inhibition 
with inverse agonists. These results yield insights into the aberrant co-regulatory 
functions of CRTC1/MAML2 and identify specific vulnerabilities that can be exploited for 
precision therapy.  
The tumor “cell of origin” is a normal cell in which a cancer-causing mutation or 
genetic hit occurs. Identification and characterization of the cell of origin is an essential 
undertaking, as a better understanding of this cell type can aid in earlier diagnosis, hint 
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at future tumor behavior, and can even inform treatment strategies. MEC tumors exhibit 
extreme cellular heterogeneity, and so it has been challenging to determine what cell 
type is responsible for tumorigenesis in this cancer. We therefore also sought to 
characterize the MEC cell of origin by generating several genetically engineered mouse 
models in which the CRTC1/MAML2 fusion oncogene is inducibly expressed in specific 
salivary gland cell populations. Our results demonstrate that CRTC1/MAML2-positive 
MEC originates from a salivary ductal precursor cell and that development of MEC 
tumors is aided by loss of Tp53 gene expression. While further studies are required to 
reduce off-target effects of oncogene induction within the cutaneous epithelia, the 
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CHAPTER 1: INTRODUCTION TO SALIVARY GLAND MALIGNANCIES 
 
1.1  Introduction 
The salivary glands are a group of exocrine organs comprised of three pairs of 
major glands (the parotid, submandibular, and sublingual glands) and hundreds of 
minor salivary glands scattered throughout the oral mucosa and the upper aerodigestive 
tract (Holsinger and Bui, 2007; Whelton, 2012). The salivary glands are responsible for 
producing serous and mucous secretions, collectively referred to as saliva, which 
function to enzymatically break down food and maintain oral health (Holmberg and 
Hoffman, 2014).  
The salivary glands begin to form early in development, with the human parotid 
gland developing as soon as the sixth embryonic week (Holsinger and Bui, 2007). Each 
gland develops through a process called branching morphogenesis, whereby 
successive rounds of epithelial budding, elongation, and lumen formation creates a 
mature gland with highly branched tree-like ductal structures (Patel et al., 2006). The 
distal ends of the ducts are capped by saliva-producing acinar cells, while the proximal 
end empties into the mouth (Figure 1). Branching morphogenesis during salivary gland 
development is a complex process orchestrated by the precise regulation of a variety of 
signaling pathways and molecular cascades, chief among which are receptor tyrosine 
kinases (RTKs). One such RTK, fibroblast growth factor receptor (FGFR), regulates cell 
proliferation and differentiation in developing tissues. Pharmacological inhibition of 
FGFR signaling blocks epithelial cell proliferation and decreases branching 
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morphogenesis in the mouse submandibular gland (Hoffman et al., 2002). Deletion of 
FGFR2b in mice results in salivary gland hypoplasia or, in some instances, complete 
lack of one or more salivary glands (Patel et al., 2006). Similarly, insulin-like growth 
factor 1 (IGF-1) signaling plays an important role in salivary gland growth and 
development (Amano and Iseki, 1993; Hoffman et al., 2002; Kerr et al., 1995; Ryan et 
al., 1992; Werner and Katz, 2004). Dysregulation of growth factor signaling, however, is 
associated with multiple types of cancer including salivary malignancies (Babina and 
Turner, 2017; Pollak, 2008; Yu and Rohan, 2000). 
Salivary cancers can arise in any of the major or the minor glands but are 
relatively rare, accounting for only 0.3-0.5% of all cancers (Eveson, 2011; Speight and 
Barrett, 2002). The diagnosis, prognosis, and treatment of salivary gland malignancies 
are complicated by a variety of factors, not least of which involves appropriate grading 
and staging. As of 2011, the World Health Organization recognized as many as 13 
benign and 24 malignant salivary gland tumor types (Eveson, 2011) Each of these 
tumors are marked by different pathologies and histologies, all of which can impact 
prognosis and treatment (Son et al., 2018). Finally, many salivary tumors are marked by 
highly variable intratumoral morphologies which can cause subjective differences in 
pathologist tumor grading, further complicating diagnosis (Betz, 2017).  
1.2  Mucoepidermoid Carcinoma 
 The most common type of malignant salivary gland tumor is mucoepidermoid 
carcinoma (MEC), which accounts for roughly 34% of all salivary malignancies (Coca-
Pelaz et al., 2015; Lujan et al., 2010; Nance et al., 2008). These tumors arise 
approximately twice as often in females, with a mean age of 45 years at the time of 
diagnosis (Chenevert et al., 2011; Cipriani et al., 2019a). MEC most often occurs in the 
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parotid gland but can arise in any of the major or minor salivary glands (Goode et al., 
1998). Less frequently, MEC may develop in other glandular tissues, including the lung, 
breast, liver, sweat glands, thyroid, and cervix (Bean et al., 2019; Cortez et al., 2018; 
Guo et al., 2014; Huo et al., 2015; Landman and Farmer, 1990; Lennerz et al., 2009; 
Roydhouse et al., 2019; Watanabe et al., 2019; Xi et al., 2012).  
 MEC tumors are characterized by three main cell types: mucous, epidermoid, 
and intermediate cells. While other cell types, such as columnar and clear cells, may 
also be present in these tumors, mucous, epidermoid, and intermediate cell types are 
the hallmarks of MEC and their presence is often considered to be diagnostic (Coca-
Pelaz et al., 2015). Mucous cells are acinar-like in appearance, with a sizable cytoplasm 
and small nucleus. They are well-differentiated and characterized by expression of 
mucins. Epidermoid cells are also terminally differentiated and are more elongated and 
polygonal in appearance. Finally, the intermediate cells are an undifferentiated cell type 
that is thought to give rise to both epidermoid and mucous cells. Notably, the relative 
proportions of each cell type are correlated with histological grade (Son et al., 2018).  
 MEC is classified as low, intermediate, or high-grade depending on a variety of 
factors, including perineural invasion, cellular differentiation, necrosis, and anaplasia 
(Coca-Pelaz et al., 2015). Low grade tumors display minimal infiltration, have a high 
proportion of mucous cells and have a better prognosis (76-95% 5-year survival) 
(Nance et al., 2008). High grade tumors are highly infiltrative, tend to recur and 
metastasize, and have a much lower 5-year survival rate (30-50%) (Brandwein et al., 
2001; Son et al., 2018). Histological grading is a critical prognostic factor and heavily 
influences treatment decisions; thus, grading needs to be accurate and reproducible 
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(Pires et al., 2004). Two main classification systems have emerged for grading MEC 
tumors: the Brandwein and AFIP systems (Brandwein et al., 2001; Cipriani et al., 2019a; 
Goode et al., 1998). In each system, points are assigned for each clinical variable and 
the sum of all points determines the tumor’s grade. Unfortunately, the two systems use 
different scoring criteria and therefore one tumor may be given two different grades 
depending on the system used. In general, the Brandwein system tends to assign 
higher tumor grades, while the AFIP system tends to assign lower tumor grades 
(Brandwein et al., 2001).   
Both low- and high-grade MEC tumors are typically treated by complete surgical 
resection, with high-grade tumors often receiving adjuvant radiotherapy (Coca-Pelaz et 
al., 2015; Pires et al., 2004). Neck dissection may be performed in cases with 
suspected regional metastasis (Eveson, 2011; Pires et al., 2004). A small number of 
clinical trials have been conducted using chemotherapy as a treatment option for MEC, 
however the results have been less than promising (Goode et al., 1998). Given the 
relative dearth of treatment options for MEC and the difficulty in reproducibly grading 
these tumors, it is critical that we gain a better understanding of the underlying 
molecular mechanisms contributing to MEC pathobiology. 
1.3 MEC Genetics and Molecular Characteristics  
The majority of MEC cases (50-85%) are characterized by a t(11;19)(q14-21; 
p12-13) chromosomal rearrangement (O’Neill, 2009; Seethala and Chiosea, 2016; 
Seethala et al., 2010; Tonon et al., 2003). This translocation fuses the first exon of 
CRTC1 (CREB-regulated transcriptional coactivator 1) to the transcriptional activation 
domain of MAML2 (Mastermind-like 2) (Figures 2A-E). Though MAML2 is involved in 
the Notch signaling pathway, CRTC1/MAML2 does not appear to dysregulate Notch 
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pathway genes, as the Notch-binding domain present in full-length MAML2 is missing in 
the fusion product. CRTC1/MAML2 does, however, bind to and constitutively coactivate 
the transcription factor cAMP response element binding protein (CREB) (Coxon et al., 
2005; Wu et al., 2005) and also exhibits a gain-of-function interaction with the master 
transcription factor MYC (Amelio et al., 2014). Moreover, CRTC1/MAML2 has been 
shown to interact with the AP-1 transcriptional complex (Canettieri et al., 2009) which 
controls cellular mitogen responses. Through CREB, AP-1, and MYC-mediated 
signaling, CRTC1/MAML2 can activate key tumor-supportive cascades that regulate cell 
survival, proliferation, and differentiation including the epidermal growth factor receptor 
(EGFR) (Chen et al., 2014) and the insulin-like growth factor 1 receptor (IGF-1R) 
signaling pathways (Musicant et al., 2021). It is likely that each of the varied 
CRTC1/MAML2 interactions, including those that are yet to be discovered, can play a 
role in promoting MEC tumorigenesis. 
Fusion-positive tumors typically display a low overall mutational burden, often 
with CRTC1/MAML2 as the sole cytogenetic abnormality (Kang et al., 2017; Martins et 
al., 2004). Additionally, CRTC1/MAML2-positive cell lines require sustained expression 
of the fusion product for their continued proliferation and survival (Komiya et al., 2006). 
These findings indicate that CRTC1/MAML2 itself functions as the primary oncogenic 
driver in fusion-positive MEC. While early literature posited that the CRTC1/MAML2 
fusion was limited to low- and intermediate-grade tumors, recent work has provided 
evidence to the contrary. Mischaracterization of adenosquamous carcinomas or salivary 
duct carcinomas as high-grade fusion-negative MEC may have disguised the true rate 
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of CRTC1/MAML2 positivity in high-grade MEC (Chenevert et al., 2011; Seethala et al., 
2010; Tirado et al., 2007).  
As the CRTC1/MAML2 gene fusion is considered to be the main driver of fusion-
positive salivary MEC, recent studies have focused on elucidating the molecular 
mechanisms driven by this oncogene in order to more accurately identify and treat this 
disease. This dissertation will detail a unique mechanism of growth factor signaling 
regulation in CRTC1/MAML2-positive MEC as well as the development of a genetically 
engineered mouse model (GEMM) that will be critical for future in vivo MEC studies.  
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CHAPTER 2: CRTC1/MAML2 ESTABLISHES A PGC1α-IGF1 CIRCUIT THAT 
CONFERS VULNERABILITY TO PPARγ INHIBITION1 
2.1  Introduction 
Mucoepidermoid carcinoma (MEC) is the most common salivary gland 
malignancy and patients with advanced recurrent or metastatic tumors often suffer from 
unresectable, lethal disease marked by a 5-year survival rate of <40% (Bell and Hanna, 
2012; McHugh et al., 2012). Salivary MECs can arise within the major or minor salivary 
glands and are characterized by significant intra-tumoral cellular heterogeneity. This 
heterogeneity is fueled by cancer stem cells that give rise to multiple cell types including 
epidermoid, mucous, and intermediate cells (Adams et al., 2015; Seethala et al., 2010; 
Stewart et al., 1945). The intermediate cells are a poorly differentiated, proliferative cell 
type and are thought to give rise to the terminally differentiated epidermoid and mucous 
cell populations. Further, the relative proportion of intermediate cells is increased in 
high-grade tumors and correlates with poor prognosis (Batsakis, 1980). Therefore, 
transcriptional programs that control cellular identity and support tumor cell functions 
can directly influence tumor grade and therefore disease progression.  
Genomic characterization of salivary MEC tumors has revealed two distinct 
tumor subtypes: “fusion-negative” and “fusion-positive”. In fusion-positive tumors, a 
recurrent t(11;19) chromosomal translocation results in the oncogenic coactivator fusion 
 
1 This chapter previously appeared in a slightly modified form as an article in the journal Cell Reports. The original 
citation is as follows: Musicant, A.M., et al. (2021). CRTC1-MAML2 establishes a PGC1α-IGF1 circuit that confers 
vulnerability to PPARγ inhibition. Cell Reports 34, 108768. 
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CRTC1/MAML2. Fusion-negative tumors, meanwhile, tend to harbor mutations in the 
tumor suppressor Tp53 (fusion-negative MEC) (El-Naggar et al., 1996; Kang et al., 
2017; Tonon et al., 2003; Wang et al., 2017). The majority of MEC cases (50-85%) 
(O’Neill, 2009) are fusion-positive and display a strikingly low somatic mutational burden 
indicating that the CRTC1/MAML2 fusion is likely the primary oncogenic driver event. 
This is not unheard of, as numerous other examples exist of cancers driven primarily by 
gene fusions in the absence of high mutational burden (Gao et al., 2018; Kadoch and 
Crabtree, 2013; Missiaglia et al., 2012; Riggi et al., 2014). Although most patients with 
low-grade, fusion-positive tumors can often be successfully treated with surgical 
resection, some CRTC1/MAML2-positive patients develop high-grade tumors that 
display recurrent, chemoradiation-resistant disease (Chen et al., 2007; Seethala and 
Chiosea, 2016; Warner et al., 2013). This underscores the critical need to develop 
targeted therapeutic strategies for this subset of salivary MEC patients.  
Transcriptional co-regulators (coactivators and corepressors) primarily serve as 
bridges between DNA-bound transcription factors and the basic transcriptional 
machinery to regulate gene expression (Rosenfeld et al., 2006). Chromosomal 
translocations that create oncogenic fusion genes involving transcriptional co-regulators 
are predicted to cause profound changes to normal developmental, homeostatic, and/or 
cellular identity programs in cancer (Lee and Young, 2013; Mitelman et al., 2019; 
Rabbitts, 1994; Tuna et al., 2019). 
Molecular properties of the chimeric CRTC1/MAML2 oncoprotein have been 
extensively characterized and reveal that the t(11;19) chromosomal translocation fuses 
the coiled-coil domain of CRTC1, which promotes binding to the transcription factor 
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cAMP response element binding protein (CREB), with the strong transcriptional 
activation domain of MAML2 (Coxon et al., 2005; Wu et al., 2005). Consequently, 
CRTC1/MAML2 functions as a rogue coactivator of the transcription factor CREB. 
However, its regulatory properties unexpectedly also include gain-of-function interaction 
with and activation of the transcription factor and proto-oncogene MYC (Amelio et al., 
2014). Unfortunately, the absence of ligand binding sites on these transcription factors 
renders them impractical targets for developing selective inhibitors (Bishop et al., 2019; 
Chen and Koehler, 2020). Thus, efforts have been directed towards defining the 
downstream pathways reprogrammed by CRTC1/MAML2. While candidate CREB and 
MYC target genes have been identified (Amelio et al., 2014; Chen et al., 2015), the 
subordinate transcriptional pathways dysregulated by CRTC1/MAML2-mediated 
activation of these transcription factors remain poorly defined. 
In this study, we performed transcriptomic profiling of fusion-positive salivary 
MEC tumors and report that CRTC1/MAML2 initiates a transcriptional cascade that 
upregulates the potent growth hormone insulin-like growth factor 1 (IGF-1) via induction 
of a PGC-1α coactivator alternative splice variant, PGC-1α4. This has functional 
consequences for the growth, survival, and oncogenic transformation of salivary gland 
precursors. Elucidating this pathway demonstrates the unique capacity of the 
CRTC1/MAML2 coactivator fusion to control complex and extensive transcriptional 
networks beyond CREB and MYC and provides the first evidence of a role for the PGC-
1α4 splice variant in human cancer pathogenesis. Integrating transcriptional profiling, 
drug screening and mechanistic data exposed multiple biologic nodes of drug 
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sensitivity, revealing that CRTC1/MAML2-positive MEC is therapeutically vulnerable to 
PPARγ inhibition. 
2.2  Results 
2.2.1 Activation of IGF-1 Signaling is a Hallmark of CRTC1/MAML2-Positive 
Salivary Mucoepidermoid Carcinoma 
IGF-1 receptor (IGF-1R) overexpression and/or ligand-induced activation of 
downstream signaling occurs in many cancers and is often required by oncogenes to 
promote transformation and malignancy (Pollak, 2008). Our previous work investigating 
the pathobiology of CRTC1/MAML2-positive MEC revealed that several genes involved 
in anabolic, pro-growth receptor tyrosine kinase (RTK) pathways, including IGF-1R 
signaling, are induced by the CRTC1/MAML2 fusion oncogene (Amelio et al., 2014). 
Here, we confirmed that IGF-1 is upregulated >100 fold upon ectopic induction of 
CRTC1/MAML2 expression (Table 1). Given the importance of IGF-1 in tumor cell 
growth and survival (Pollak, 2008; Yu and Rohan, 2000) and in salivary gland growth 
and development (Amano and Iseki, 1993; Kerr et al., 1995; Ryan et al., 1992; Werner 
and Katz, 2004), we hypothesized that IGF-1R signaling plays a key role in salivary 
MEC tumorigenesis. To validate the clinical relevance of this finding, we first obtained a 
cohort of eighteen human primary salivary MEC samples from the surgical pathology 
department at UNC Hospitals (Chapel Hill, NC) and assessed CRTC1/MAML2 status 
(Figure 3). In accordance with previous reports (Birkeland et al., 2017), we found that 
ten of these samples (56%) were CRTC1/MAML2-positive. Next, we performed RNA 
sequencing on all of these MEC samples (fusion-positive and -negative) to identify 
differentially expressed genes (DEGs) relative to six normal salivary gland controls. 
Unbiased and unsupervised hierarchical clustering revealed that CRTC1/MAML2-
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positive tumors constitute a gene expression subtype distinct from CRTC1/MAML2-
negative tumors (Figure 4). This finding is in agreement with recent studies that 
suggested that CRTC1/MAML2-positive and -negative MEC are two distinct tumor types 
that are driven by distinct signaling mechanisms (Kang et al., 2017; Sheth et al., 2020; 
Wang et al., 2017). Notably, we identified IGF-1 among 3,971 up-regulated genes that 
are significantly differentially expressed (fold change > 2 and padj < 0.05) in 
CRTC1/MAML2-positive tumors relative to normal salivary glands. Gene set enrichment 
analysis (GSEA) of curated gene lists within the Molecular Signatures Database 
(MSigDB) revealed that IGF-related signaling pathways rank among the top signatures 
associated with CRTC1/MAML2-positive tumors. Thus, we generated a refined gene list 
(Musicant_MEC_CRTC1-MAML2_IGF1) by curating IGF-1 pathway-related genes with 
a fold change > 2 (padj < 0.05) that reflect a gene signature specific to CRTC1/MAML2-
positive MEC tumors (Figures 5A and 5B). We then evaluated the ability of our curated 
Musicant_MEC_CRTC1-MAML2_IGF1 gene list to distinguish CRTC1/MAML2-positive 
MEC by comparison with the established MSigDB GNF2_IGF1 gene list (Figures 6A 
and 6B). Importantly, we examined gene expression in these MEC cases by qRT-PCR 
and found that CRTC1/MAML2 copy number is significantly correlated (r2 = 0.7251; p < 
0.0001) with IGF-1 expression (Figure 7). Therefore, these results demonstrate that 
CRTC1/MAML2-positive MEC is characterized by increased IGF-1 expression and 
suggest an important role for IGF-1R signaling in this MEC tumor subtype. 
2.2.2 CRTC1/MAML2-Positive MEC Tumor Cell Lines Display Selective 
Sensitivity to Targeted IGF-1R Inhibition 
To investigate the role of constitutive IGF-1 expression and downstream 
signaling in CRTC1/MAML2-positive MEC cells, we obtained a panel of five MEC 
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(H292, H3118, HMC1, HMC3A, and HMC3B) and three epidermoid (A253, A388, and 
A431) cell lines. We first confirmed that all of the MEC cell lines are positive for 
expression of the CRTC1/MAML2 fusion transcript and that all of the epidermoid 
carcinoma cell lines are fusion-negative (Figure 8A). Further, all CRTC1/MAML2-
positive MEC cell lines display robust IGF-1 expression relative to CRTC1/MAML2-
negative cell lines, and this increased IGF-1 expression significantly correlates (r2 = 
0.8664; p = 0.0008) with CRTC1/MAML2 expression in fusion-positive MEC cells 
(Figures 8B and 8C). Finally, histologic analysis of tumor xenografts confirms that 
CRTC1/MAML2-positive salivary MEC cell lines generate significant intra-tumoral 
cellular heterogeneity, which mimics the mucous, epidermoid, and intermediate cell 
types characteristic of human salivary MEC, demonstrating that these cell lines are 
capable of forming representative MEC tumors in vivo (Behboudi et al., 2006; Bell and 
Hanna, 2012; Warner et al., 2013). In contrast, fusion-negative epidermoid carcinoma 
cells generate xenograft tumors with typical solid epidermoid morphology (Figure 9). 
Importantly, immunohistochemical staining demonstrated that CRTC1/MAML2-positive 
tumors are associated with increased IGF-1 production in vivo (Figure 9).  
To test whether CRTC1/MAML2-positive MEC cells are dependent on IGF-1 
signaling, we performed a small molecule drug screen focused on RTK inhibitors 
(RTKis) at concentrations ranging from 10 nM to 10 μM in all five CRTC1/MAML2-
positive cell lines relative to a fusion-negative control cell line (Figure 10A). Calculation 
of the Z’-factor demonstrated robust assay quality such that the distribution between the 
positive (Bortezimib) and negative (DMSO) controls indicates low likelihood of false 
positive hits (Z’ > 0.75) (Figure 10B). Multiple independent inhibitors targeting IGF-1R 
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and EGFR emerged as significant hits (p ³ 3SD) in this screen (Figure 10A). Notably, 
EGFR has been explored as a therapeutic target, though with limited clinical success 
(Chen et al., 2014), and its emergence as a significant hit validated the robustness of 
our screen results. Compared to the non-MEC fusion-negative control cells, IGF-1R 
inhibitors induced selective and robust cell death in all CRTC1/MAML2-positive cell 
lines (Figure 10C), indicating the relative importance of IGF-1/IGF-1R signaling in 
CRTC1/MAML2-positive MEC. Dose titrations of two separate IGF-1R inhibitors, BMS-
754807 and picropodophyllin (PPP), confirmed that the CRTC1/MAML2-positive cell 
lines are sensitive to IGF-1R inhibition, with IC50s for both compounds in the low nM 
range (Figure 11 and Table 2).  
2.2.3  IGF-1R Signaling is Critical for CRTC1/MAML2-Positive MEC Tumor Cell 
Growth and Survival 
We next wanted to examine the functional role of IGF-1R signaling on human 
CRTC1/MAML2-positive MEC cell growth and survival via pharmacologic inhibition 
and/or genetic knockdown (validated in Figures 12A-E). Live-cell, kinetic proliferation 
assays revealed that wild-type HMC3A cells reach 50% confluency after 28 hr (GC50 = 
28 hr), but pharmacologic inhibition of IGF-1R with PPP significantly increases this time 
to confluency (p < 0.05) relative to control (Figure 13A). To test if blocking IGF-1R 
impairs the tumorigenic potential of MEC cells to grow as clonogenic colonies ex vivo, 
CRTC1/MAML2-positive cells were plated at low density and observed for colony 
formation. We found that both PPP and BMS-754807 markedly blunted the clonogenic 
potential of several independent MEC cell lines relative to vehicle-treated cells (Figures 
13B and 13C). Several recent studies have documented the existence of cancer stem 
cell (CSC) subpopulations within various head and neck cancers, including salivary 
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MEC, and these CSCs are associated with malignant potential (Adams et al., 2015; 
Curtarelli et al., 2018; Keysar et al., 2017). Since tumor spheroids are uniquely enriched 
for CSCs, we also quantified the effects of PPP on 3D tumor spheroid formation in 
Matrigel and found that sustained IGF-1R inhibitor treatment (7 days) significantly 
blocks (p < 0.0001) MEC 3D sphere formation (Figure 13D). Finally, we investigated the 
mechanism underlying the observed decrease in proliferation and tumorigenic potential 
and found that PPP stimulates a significant dose-dependent increase (p < 0.001) in 
apoptosis compared to vehicle-treated cells (Figure 13E). 
2.2.4  CRTC1/MAML2 Establishes a Synthetic PGC-1α4 Circuit that Regulates 
IGF-1 Expression in MEC Tumor Cells 
To determine the mechanism by which CRTC1/MAML2 regulates IGF-1 
expression in MEC cells, we utilized an engineered CRTC1/MAML2-inducible stable cell 
line (Amelio et al., 2014) (doxycycline-regulated HEK293-CMVTetRTetOC1/M2) (Figure 
14A). Overexpression of CRTC1/MAML2 in this cell line significantly increases IGF-1 
expression at both the transcript and protein levels (Figures 14B-E). CRTC1/MAML2 
coactivates the transcription factor CREB, which in turn binds to specific DNA 
sequences called cAMP-response elements (CREs). Examination of IGF-1 promoter 
sequences revealed a non-canonical CRE site, indicating that CRTC1/MAML2 could 
possibly drive IGF-1 signaling through direct upregulation of IGF-1 transcription. 
However, chromatin immunoprecipitation (ChIP) assays failed to identify 
CRTC1/MAML2 enrichment at the IGF-1 promoter relative to the control canonical 
CREB target gene NR4A2 (Figure 15A). 
We previously showed that CREB regulates stress-inducible expression of a 
PPARγ coactivator 1a splice variant (PGC-1a4) transcribed from an upstream (~13 
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Kbp) distal promoter of the PGC-1a locus (Bruno et al., 2014), which in turn selectively 
regulates IGF-1 expression (Ruas et al., 2012). Thus, we performed ChIP assays and 
identified CRTC1/MAML2 enrichment specifically at this distal PGC-1a promoter (Figure 
15A). Moreover, luciferase reporter assays confirmed that CRTC1/MAML2 activates the 
distal CRE-containing PGC-1a promoter but not the proximal promoter (Figure 15B), 
suggesting that CRTC1/MAML2 may indirectly regulate IGF-1 expression by controlling 
PGC-1a4 expression in MEC cells. We next performed shRNA-mediated 
CRTC1/MAML2 knockdowns and found that PGC-1a4 levels are dramatically reduced 
similar to the control NR4A2, confirming that CRTC1/MAML2 upregulates PGC-1a4 
transcription (Figures 15C and 15D). Expression of inducible dominant-negative CREB 
(A-CREB) in a stable MEC cell line (HMC3A-PGKTetOn3GTRE3GSA-CREB) also blocked 
PGC-1a4 expression, supporting the role of CREB-dependent regulation of the PGC-1a 
distal promoter by CRTC1/MAML2 (Figure 15E). To examine the kinetics of this 
expression circuit more closely, we performed a time course experiment in 
CRTC1/MAML2-inducible stable cells and found that PGC-1a4 transcripts peak at 24 
hrs (~12 hr after CRTC1/MAML2 induction) while IGF-1 transcripts begin to rise at ~24-
36 hrs, but peak 48 hrs after CRTC1/MAML2 induction and 24 hrs after PGC-1a4 
upregulation (Figure 16A). Notably, compared to the other PGC-1a transcript isoforms, 
CRTC1/MAML2-positive MEC cell lines are all characterized by robust expression of the 
PGC-1a4 variant relative to CRTC1/MAML2-negative cell lines (Figures 16B and 16C). 
To further validate that the PGC-1a4 variant is responsible for inducing IGF-1 
expression, we engineered MEC cell lines with an inducible CRISPR interference 
(dCas9-KRAB; CRISPRi) system (Gilbert et al., 2013). Unique sgRNAs that either 
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repress expression of all PGC-1a isoforms or that selectively repress only the PGC-1a1 
variant revealed that the canonical PGC-1a1 variant has no effect on IGF-1 regulation 
(Figures 17A and 17B). In contrast, repressing transcription of all variant isoforms 
causes a significant decrease (p < 0.0001) in IGF-1 expression (Figures 17A and 17B), 
further indicating that PGC-1a4 regulates IGF-1. To confirm that this non-canonical 
PGC-1a4 isoform is responsible for promoting IGF-1 transcription, we next generated a 
PGC-1a4-inducible stable cell line (doxycycline-regulated HEK293-
PGKTetOn3GTRE3GSPGC-1α4; validated in Figures 18A and 18B) and confirmed that 
selective overexpression of the PGC-1a4 splice variant is sufficient to upregulate IGF-1 
expression, thus acting as the intermediate to CRTC1/MAML2 (Figure 18C). Finally, 
shRNA-mediated knockdown of PGC-1a4, as well as other components within this 
signaling circuit (IGF-1R and CRTC1/MAML2) significantly blunts proliferation of 
CRTC1/MAML2-positive MEC cells (Figure 19), confirming that PGC-1a4 is both 
necessary and sufficient for activating the IGF-1 signaling circuit in fusion-positive MEC.  
2.2.5 The PGC-1a4 Co-Regulator Activates PPARγ-dependent Transcription of 
IGF-1 in CRTC1/MAML2-Positive MEC Cells 
PGC-1a is a co-activator that binds to the transcription factor peroxisome 
proliferator-activated receptor gamma (PPARγ) to exert its effects on transcription of 
metabolic target genes (Semple et al., 2006; Sonoda et al., 2008). Strikingly, analysis of 
the IGF-1 locus identified three canonical PPAR-response element (PPRE) binding 
motifs within the IGF-1 promoter region (Figure 20A). To test whether PGC-1a4 co-
activates PPARγ to modulate IGF-1 transcription, we first confirmed that overexpression 
of CRTC1/MAML2 induces transcription of an IGF-1 promoter-driven luciferase reporter 
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comparable to levels of induction observed with a PPRE-driven luciferase reporter 
(Figures 20B and 20C). Importantly, functional characterization revealed that both the 
PPRE-driven and the IGF-1 promoter-driven luciferase reporter constructs are 
responsive to the PPARγ agonist GW1929, indicating that the cloned IGF-1 promoter 
fragment includes the PPRE motifs that recruit PPARγ (Figures 21A and 21B). 
Therefore, we next tested whether the PPARγ inverse agonist SR10221, which 
functions to recruit transcriptional co-repressors to PPARγ that repress target gene 
transcription, is effective at inhibiting IGF-1 expression. Treatment with SR10221 
effectively downregulated PPARγ-mediated transcriptional activity of the IGF1-
Luciferase reporter in a dose-dependent manner to below basal levels, comparable to 
that observed with the PPRE-Luciferase reporter (Figures 21C and 21D). Similarly, 
shRNA-mediated knockdown of PPARγ resulted in a robust decrease in IGF-1 
expression (Figures 22A and 22B) and potent induction of apoptosis as evidenced by 
significant increases (p < 0.05) in caspase 3/7 activation (Figure 22C). This indicates 
that the PGC-1a4:PPARγ circuit controls IGF-1 expression and suggests that drugs 
targeting PPARγ may provide therapeutic benefit against CRTC1/MAML2-positive 
salivary MEC. 
2.2.6 PPARγ Inverse Agonists Suppress CRTC1/MAML2-Positive MEC Tumor 
Growth 
To investigate the functional role of PPARγ dependency on MEC cell growth and 
survival, we tested the effects of several PPARγ inverse agonists in our panel of 
CRTC1/MAML2-positive MEC cell lines. First, to determine the efficacy of PPARγ 
inverse agonists as anti-MEC agents, we assessed the effect of three different inverse 
agonists (SR10221, SR2595, and T0070907) on cancer cell viability using the full panel 
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of CRTC1/MAML2-positive MEC cell lines (Figure 23A and Table 3). Dose titration of 
these compounds revealed that SR10221 potently reduced cancer cell viability at low 
micromolar concentrations (half-maximal inhibitory concentration [IC50] ~70 – 150 μM) in 
HMC3A cells (Table 3). Further, treatment with SR10221 or SR2595 decreased 
expression of IGF-1 (Figures 23B and 23C) as well as the canonical PPARγ target 
genes PGK1 and PKM2 in CRTC1/MAML2-positive MEC cells (Figure 23B). Treatment 
of CRTC1/MAML2-positive cell lines with sub-lethal doses of SR10221 (½ IC50) 
significantly decreased proliferation, 2D colony formation, and 3D tumor spheroid 
growth (Figures 24A-C). Moreover, this decreased growth and tumorigenic potential 
coincided with potent induction of apoptosis as evidenced by significant increases in 
caspase 3/7 activation (Figure 24D). 
To determine the efficacy of PPARγ inverse agonists in vivo, we first tested the 
potency of SR10221 in subcutaneous HMC3A tumor xenograft models labeled with our 
LumiFluor bioluminescent reporter (Schaub et al., 2015). Tumor xenografts were 
allowed to grow to a palpable size (approximately 50 mm3) and animals were 
randomized into two cohorts. These cohorts then received intraperitoneal (i.p.) 
administration of 20 mg/kg SR10221 or vehicle control once daily for three weeks which 
resulted in the significant inhibition (p < 0.0001) of HMC3A tumor xenograft growth 
(Figures 25A-C). Similarly, we also tested the in vivo potency of SR2595 since it 
displays superior pharmacokinetic properties, although we administered SR2595 at 60 
mg/kg since SR10221 was shown to possess ~2- to 3-fold greater potency in vitro 
(Marciano et al., 2015). Treatment with SR2595 at this concentration was generally 
well-tolerated without body weight loss (Figure 25D), but significantly blocked the 
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growth of CRTC1/MAML2-positive MEC tumor xenografts (Figures 25E-G). Collectively, 
these results suggest that inhibition of IGF-1 signaling using PPARγ inverse agonists 
alone or in combination with IGF-1R inhibitors may be a viable therapeutic strategy for 
the targeted treatment of CRTC1/MAML2-positive MEC. 
2.3 Discussion 
Recurrent chromosomal translocations that generate novel gene fusions have 
long been known to have the potential to function as cancer drivers (Rabbitts, 1994, 
2009; Rowley, 2001). However, the advent of fusion detection algorithms applied to 
“omics”-level data has not only enabled the discovery of additional gene fusions 
composed of splicing factors, signal transduction proteins, transcription factors, and/or 
transcriptional co-regulators (Fernandez-Cuesta et al., 2015; Jang et al., 2020; Kumar-
Sinha et al., 2015) but has also aided in elucidating the direct functional consequences 
of these fusions on cellular processes such as signaling and gene expression 
(Latysheva et al., 2016; Lee and Young, 2013). Interestingly, these aberrant processes 
are frequently unique to distinct gene fusions which may in turn be characteristic of 
specific cancer subtypes (Fishbein et al., 2017; Gao et al., 2018). CRTC1/MAML2 
represents one such recurrent gene fusion composed of two transcriptional co-
activators that is pathognomonic for mucoepidermoid carcinoma (O’Neill, 2009; Tonon 
et al., 2003). Here, we report that the CRTC1/MAML2 fusion oncogene directs profound 
reprogramming of transcriptional networks and establishes a synthetic IGF-1 signal 
circuit through aberrant expression of an alternative PGC-1a splice variant in salivary 
MEC (Figure 26). 
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Despite being the most common salivary gland malignancy, MECs are relatively 
rare compared to other head and neck cancers and consequently the pathobiology of 
CRTC1/MAML2 remains poorly understood. While it is clear that patients with advanced 
stage and/or high-grade tumors display significantly worse overall survival (Chen et al., 
2013), the prognostic value of fusion status has recently been challenged (Seethala and 
Chiosea, 2016). Most MEC patients are treated with surgical excision, which is 
sometimes accompanied by adjuvant radiotherapy (Nance et al., 2008). Unfortunately, 
resistance to chemoradiotherapies and a lack of targeted therapies for 
recurrent/metastatic disease poses significant challenges to treating patients with 
aggressive MEC tumors. For example, recent studies have indicated that paclitaxel, 
trastuzumab, or RTK inhibitors may be viable treatments for fusion-positive MEC, 
however preliminary results show only modest responses to these treatments (Coca-
Pelaz et al., 2015; McHugh et al., 2012) emphasizing the need for performing thorough 
molecular profiling studies to aid in the development of new targeted therapies. 
As a transcriptional coactivator gene fusion, CRTC1/MAML2 interacts with and 
activates two master transcription factors: CREB and MYC (Amelio et al., 2014; 
Tasoulas et al., 2019). Unfortunately, intrinsic disorder and the lack of available binding 
pockets has made designing small molecules that can effectively target transcription 
factors a major challenge (Bishop et al., 2019; Chen and Koehler, 2020; Wachtel and 
Schäfer, 2018). In addition, two recent genomics studies revealed that CRTC1/MAML2 
is the primary oncogenic driver in most salivary MECs and that these fusion-positive 
cases lack other cooperating mutations that occasionally serve as actionable targets in 
other cancers (Kang et al., 2017; Wang et al., 2017). In this study, we set out to identify 
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the most significantly altered and clinically relevant target genes and pathways 
downstream of CRTC1/MAML2 that can be exploited to develop novel therapeutic 
approaches for treating patients with salivary MEC. Using transcriptomic profiling, we 
show that CRTC1/MAML2 expression is correlated with increased IGF-1 expression 
and pathway activation in salivary MEC tumors. Autocrine and paracrine activation of 
the IGF-1 pathway is known to promote growth and survival of multiple tumor types 
(Pollak, 2008; Yu and Rohan, 2000). Notably, endocrine IGF-1 signaling is broadly 
involved in normal tissue growth and development through its stimulation of IGF-1R and 
has been shown to play critical roles in regulating salivary gland growth and 
development and in stimulating regeneration following injury (Amano and Iseki, 1993; 
Kerr et al., 1995; Ryan et al., 1992; Werner and Katz, 2004), thus supporting an 
important role for aberrant IGF-1 expression in salivary tumor development. Through 
the use of bioinformatics analyses and small molecule drug screening, we were 
successful in pinpointing IGF-1R as an actionable target in salivary MEC, suggesting 
that treatments directed against IGF-1R may provide therapeutic benefit. However, 
despite early excitement surrounding the potential utility of these treatments for many 
cancers (Gualberto and Pollak, 2009), targeting the IGF axis has yielded disappointing 
results in clinical trials (Chen and Sharon, 2013; Denduluri et al., 2015). Therefore, we 
also sought to explore the underlying mechanism governing IGF-1 activation by 
CRTC1/MAML2 in salivary MEC and identified unexpected rewiring of this growth factor 
signal circuit coordinated by aberrant expression of an alternatively spliced target gene 
of CRTC1/MAML2, the PGC-1a4 variant. 
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PGC-1a has been shown to exert oncogenic (Frattini et al., 2018) or tumor 
suppressive (Torrano et al., 2016) activity depending on cell type and context-
dependent metabolic cues (Mastropasqua et al., 2018; Sancho et al., 2015; Xing et al., 
2017). Notably, the PGC-1a family of transcriptional coactivators is composed of an 
expanding list of transcript isoforms generated by multiple promoters and alternative 
pre-mRNA splicing, and these resulting protein variants are known to display unique 
functional properties (Martínez-Redondo et al., 2015, 2016). The majority of the current 
literature focuses on the role of the major PGC-1a transcript, PGC-1a1, in various 
cancers including melanoma (Luo et al., 2016, 2020; Vazquez et al., 2013) and prostate 
cancer (Torrano et al., 2016; Valcarcel-Jimenez et al., 2019; Wallace and Metallo, 
2016). However, rare, alternatively spliced transcripts such as PGC-1a4 are emerging 
as key players in multiple cancer types and thus represent an attractive target for 
pharmacological intervention (Kimes et al., 2014; Oltean and Bates, 2014; Wang and 
Lee, 2018; Zhang and Manley, 2013). To date, though, the specific role of these PGC-
1a alternative splice variants in cancer has remained elusive. We demonstrate that the 
CRTC1/MAML2 fusion selectively induces CREB-dependent expression of the PGC-
1a4 splice variant, which we and others have shown is associated with IGF-1 
expression in anabolic skeletal muscle (Bruno et al., 2014; Ruas et al., 2012; Tasoulas 
et al., 2019). We confirm here that CRTC1/MAML2 directs similar anabolic pro-growth 
and pro-survival signaling by coordinating this autocrine PGC-1a4 – IGF-1 signal circuit 
in fusion-positive salivary MEC. 
A model that may explain the transcriptional and pre-mRNA splicing effects of 
CRTC1/MAML2 on PGC-1a4 is that this fusion acquires a strong transcriptional 
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activation domain from MAML2 and retains the CREB binding domain of CRTC1, while 
the splicing domain normally present in full-length CRTC1 is deleted (Amelio et al., 
2009; Tasoulas et al., 2019). Importantly, the PGC-1a4 variant retains the activation 
domain common to other PGC-1a transcript isoforms, which mediates binding to 
nuclear hormone receptor transcription factors such as PPARγ (Li et al., 2008; 
Martínez-Redondo et al., 2015; Sonoda et al., 2008). Similar to PGC-1a, dichotomous 
roles for PPARγ have been described with evidence pointing to oncogenic activity in 
some cancers but tumor suppressor actions in other cancers. This is supported by data 
using PPARγ agonists or antagonists, respectively (Goldstein et al., 2017; Kardos et al., 
2016; Khandekar et al., 2018; Zou et al., 2019). We demonstrate here that PGC-1a4 
upregulates IGF-1 in a PPARγ-dependent manner in CRTC1/MAML2-positive salivary 
MEC, which sensitizes these tumor cells to treatment with PPARγ inverse agonists. 
Given the limitations of anti-IGF1R monotherapy, the identification of PPARγ inverse 
agonists as potential therapeutics for the treatment of MEC is particularly exciting. A 
limitation of this study, however, is that therapeutic effects achieved with the PPARγ 
inverse agonists SR10221 and SR2595 were in the low micromolar range, despite the 
fact that functional ligand binding and induced PPARγ conformational changes are 
possible in the nanomolar range (Marciano et al., 2015; Shang et al., 2020). These 
differences in the inverse agonist concentrations required to achieve corepressor-
dependent PPARγ repression may be due to higher binding affinity of the PGC-1a4 
variant with PPARγ and/or increased levels of competing endogenous ligands (e.g. 
esterified lipids) in salivary MEC cells. Interestingly, our bioinformatic analyses revealed 
that several metabolic pathways with the potential to directly influence endogenous 
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ligand levels, including lipid biosynthesis and modification pathways, are significantly 
elevated in CRTC1/MAML2-positive salivary MEC. 
In summary, our study identifies the CRTC1/MAML2 fusion oncogene as a 
master regulator of transcriptional networks that promote tumorigenic processes in part 
via a novel PPARγ-dependent PGC-1a4 – IGF-1 signaling circuit (Figure 26). Therefore, 
elucidation of the CRTC1/MAML2-regulated PGC-1a4-dependent transcriptional 
program may open new avenues for the identification of other pathways that can be 
exploited in order to stratify patients suitable for precision therapies. Our findings 
establish that targeting this ‘synthetic’ signaling circuit via IGF-1R inhibition or PPARγ 
inverse agonism, either individually or in combination, is a potential therapeutic option 




CHAPTER 3: DEVELOPING AN AUTOCHTHONOUS MOUSE MODEL OF 
MUCOEPIDERMOID CARCINOMA 
 
3.1  Introduction 
In his 1971 State of the Union address, President Richard Nixon declared a “war 
on cancer”, proposing that $100 million be funneled into “an intensive campaign to find 
a cure for cancer” (Coleman, 2013). Though Nixon was misguided in his use of the word 
“cure”– we now know that there is no single cure for all cancers – the aftermath of his 
declaration was marked by many successes including improved detection, diagnosis, 
and treatment options (DeVita Jr, 2004; Sporn, 1996). As a result, today’s cancer 
patients fare much better than those fifty years ago – with improved survival times and 
quality of life – though there is significant room for improvement. The 2016 launch of the 
Obama administration’s cancer “moonshot” project (Kaiser and Couzin-Frankel, 2016; 
Singer et al., 2016) is helping to promote significant advances in early disease detection 
and personalized medicine, however patients with advanced disease often do not 
survive beyond five years from their initial diagnosis and may respond poorly to novel 
therapeutics. Therefore, it is important that the field of cancer biology makes use of the 
best available tools to investigate the mechanisms underlying tumorigenesis and to test 
potential new therapies (Sharpless and DePinho, 2006). 
Direct study of human tumor samples is important and can provide insights into 
certain tumor-associated molecular events, however these endeavors can only provide 
a snapshot of the tumorigenic process. In order to elucidate the complexities of disease 
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progression and test novel therapeutics, the development of preclinical model systems 
is critical (Walrath et al., 2010). In cancer biology, one of the most commonly used 
model systems is the immortalized cell line. Cell lines are typically derived from human 
tumor biopsies/resections that have been adapted to grow in highly controlled lab 
culture settings for use in in vitro assays. However, cells grown in a dish are incapable 
of recapitulating important aspects of tumor biology, including the stromal 
microenvironment and intratumoral heterogeneity (Bleijs et al., 2019), both of which can 
have significant effects on tumor behavior and patient outcomes. Therefore, many 
cancer studies make use of in vivo systems such as xenograft models and/or 
genetically engineered mouse models (GEMMs).  
In a xenograft model, immortalized human cells or primary resected tumor 
samples are subcutaneously implanted into immunodeficient mice. The xenografted 
tumor can then grow in an in vivo environment that more accurately recapitulates 
aspects of the human tumor microenvironment, such as access to both growth factors 
and vasculature. Xenograft models are relatively simple and inexpensive, making them 
valuable tools for both academic and industrial research (Sharpless and DePinho, 
2006). However, these models present their own set of problems. For example, 
xenograft studies are often performed on a relatively short time scale, which does not 
provide enough time for the development of a true cancer stromal microenvironment 
and may overestimate a tumor’s susceptibility to drug treatment (Walrath et al., 2010). 
Moreover, xenografts are typically established using an immortalized cell line, which is 
monoclonal by nature. The process of establishing this monoculture may select for a 
cell line that, when xenografted, generates tumors that underrepresents the true 
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complexity and heterogeneity of the original human tumor (Bleijs et al., 2019). Finally, 
commonly used xenograft models rely on immunodeficient mice, which lack a functional 
immune system and thus are not amenable to the testing of immunotherapies and 
immunomodulatory agents, both of which have recently manifested as an exciting area 
of research (Frese and Tuveson, 2007; Leon et al., 2020; Sharpless and DePinho, 
2006).   
Thus, since the mid-1980s (Sharpless and DePinho, 2006), focus has shifted to 
mice that have been genetically modified to predispose them to tumors mimicking those 
seen in humans, both in terms of genetic makeup and site of origin. GEMMs are 
superior to xenograft models in that they allow for the interaction of host immune cells 
with the tumor throughout all stages of malignancy. They also allow for the co-
development of the tumor stroma with the tumor itself (Walrath et al., 2010). GEMM 
technology has advanced significantly since its initial introduction. While early models 
often involved whole-body, constitutive knockout or overexpression of target genes, 
often resulting in issues such as embryonic and neonatal lethality (Chavez-Reyes et al., 
2003; Dang et al., 2003; de Oca Luna et al., 1995; Wakabayashi et al., 2003), current 
models are more refined, combining cell-specific genetic alterations with inducible 
systems such as Cre/LoxP and Flp-Frt technology (Lewandoski, 2002; Nagy, 2000; 
Rodriguez et al., 2000; Sorrell and Kolb, 2005) to more accurately model the 
spontaneous, localized genetic changes that lead to human tumor development. 
Despite these advancements in GEMM design, there is a dearth of available 
models for rare, understudied cancers. MEC, which is the most common type of 
malignant salivary gland tumor but affects only 1 in every 100,000 people (O’Neill, 
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2009), is one such disease where a validated pre-clinical GEMM has not been 
generated. Unfortunately, the extreme cellular heterogeneity observed in MEC tumors 
has hindered the development of a GEMM model by obscuring the cell of origin for this 
tumor type. 
The tumor “cell of origin” is a normal cell in which a cancer-causing mutation or 
genetic hit first occurs (Visvader, 2011). This cell can then proliferate rapidly and form a 
full-blown tumor. Importantly, the concept of a tumor cell of origin should be 
distinguished from that of a cancer stem cell (CSC), which is a self-renewing cell that 
can give rise to the full complement of tumor cell subpopulations. In other words, the 
cell of origin is a tumor-initiating cell, while CSCs are tumor-propagating cells (Visvader, 
2011). In many cancer types, the cell of origin and the CSC are phenotypically distinct. 
Identification and characterization of the cell of origin is an essential undertaking in the 
field of cancer research, as a better understanding of this cell type can aid in earlier 
diagnosis, hint at future tumor behavior, and even inform treatment strategies (Hoadley 
et al., 2018). Further, establishing the appropriate cell of origin is crucial for developing 
accurate disease models, as overexpression of an oncogene might drive malignant 
processes in one cell type but not in another (Bailleul et al., 1990; Brown et al., 1998; 
Perez-Losada and Balmain, 2003). While the histopathology of an individual tumor may 
sometimes provide insights into the cell of origin, MEC tumors exhibit significant cellular 
heterogeneity (Coca-Pelaz et al., 2015; Schwarz et al., 2011), and so it has been 
challenging to determine what cell type is responsible for tumorigenesis in this cancer.  
The salivary glands are highly branched tree-like structures (Patel et al., 2006) 
composed of three main cell types: ductal, acinar, and myoepithelial cells (Figure 1). 
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Each of these differentiated cell populations is maintained by slow turnover and 
repopulation via lineage-restricted progenitor cells (Rocchi et al., 2021; Zajicek et al., 
1989). A putative stem cell population can also undergo accelerated cell division and 
differentiation in order to repopulate the salivary gland following extensive damage or 
injury. Work from other groups has suggested that these stem cells can be found within 
either the intercalated duct or acinar cell populations of the mature salivary glands. 
These claims are based on the roles of the two cell populations in active cell division 
and repopulation of damaged salivary glands (Emmerson et al., 2017; Holmberg and 
Hoffman, 2014; Knosp et al., 2012; Kwak et al., 2016; van Luijk et al., 2015; Maimets et 
al., 2016; May et al., 2018; Weng et al., 2018). 
Stem cells are frequently favored as potential tumor cells of origin, as their 
plasticity, longevity, and capacity for self-renewal could conceivably contribute to the 
development of heterogeneous tumors (Visvader, 2011). These cells may reactivate 
dormant developmental signaling pathways in order to drive the rapid cellular 
proliferation seen in many malignancies. Thus, our hypothesis is that CRTC1/MAML2-
positive MEC arises in an early salivary progenitor cell that is capable of differentiating 
into the multiple cell types seen in MEC tumors. In this study we utilized acinar and 
ductal cell-specific promoters (Maruyama et al., 2016) to drive inducible CRTC1/MAML2 
overexpression and Tp53 loss in mice in order to (1) characterize the MEC cell of origin 





3.2.1 Targeted Transgene Expression is Achieved via Cell Type-Specific 
Promoters 
We developed multiple transgenic lines to study the contribution of various 
salivary gland cell types to MEC development. Each of these lines allowed for inducible 
expression of CRTC1/MAML2 (LoxP-STOP-LoxP-CRTC1/MAML2, abbreviated as 
C1/M2) and/or our bioluminescent LumiFluor reporter (LoxP-STOP-LoxP-LumiFluor, 
abbreviated as LumiFluor) (Schaub et al., 2015). Expression of each transgene was 
controlled by a tamoxifen-inducible Cre recombinase (CreERT2) whose expression was 
driven by the promoter of a cell type-specific gene: Dcpp1, Mist1, or Krt14 (abbreviated 
as DcppCre, MistCre, and K14Cre, respectively) (Maruyama et al., 2016; Shi et al., 2009; 
Vasioukhin et al., 1999) (Figure 27). Dcpp1 is expressed in the serous demilune cells of 
the sublingual gland and also in the intercalated ductal cells (Bekhor et al., 1994), which 
have been suggested as the location of a salivary gland stem cell population. Mist1 is 
expressed in salivary gland serous and seromucous acinar cells as well as in pancreatic 
acinar cells and secretory cells of the stomach, prostate and seminal vesicle (Pin et al., 
2000, 2001). Krt14 is expressed in basal cells of the salivary intercalated, striated, and 
excretory ducts and is also expressed in basal epithelial cells (Su et al., 1993).  
We first assessed transgene activation by measuring bioluminescent signal in the 
head and neck region of MistCre-LumiFluor, K14Cre-LumiFluor, DcppCre-LumiFluor, and 
control mice at various time points (Figure 28) following tamoxifen administration. 
K14Cre-LumiFluor animals displayed bioluminescent signal in the oral and salivary gland 
regions but also displayed significant transgene activation in epithelial tissues, including 
the paws and ears. MistCre-LumiFluor animals displayed activation specifically in the 
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submandibular and sublingual gland region, while DcppCre-LumiFluor animals did not 
exhibit any significant bioluminescent signal in the salivary glands at all. 
We then analyzed CRTC1/MAML2 transcript levels in fresh-frozen salivary gland 
tissue from DcppCre-C1/M2, MistCre-C1/M2, K14Cre-C1/M2, and control animals to 
determine whether transgene activation was occurring in the submandibular, sublingual, 
or parotid glands. Within 4 months of tamoxifen administration, DcppCre-C1/M2, MistCre-
C1/M2, and K14Cre-C1/M2 animals all displayed robust submandibular gland expression 
of CRTC1/MAML2 and low levels of expression in the sublingual and parotid glands 
(Figure 29). 
3.2.2  CRTC1/MAML2-Positive Salivary MEC Originates in a Ductal Cell 
Following confirmation of CRTC1/MAML2 expression in each transgenic mouse 
line, we wanted to investigate the histological and potential tumorigenic effects of 
oncogene overexpression in each of the three major salivary glands. Though we 
achieved robust CRTC1/MAML2 expression in the salivary glands of MistCre-C1/M2 
mice, tissue samples from these animals did not display any histological differences 
compared to control animals (Figure 30). However, oncogene induction within the 
intercalated ductal cells and serous demilune cells (DcppCre-C1/M2 mice) resulted in 
slight ductal hyperplasia and dysplasia (Figure 30). Similarly, CRTC1/MAML2 induction 
in the basal duct cells (K14Cre-C1/M2 mice) did not result in tumor formation but did 
induce a dysplastic/hyperplastic morphology (Figure 30).  
Notably, overexpression of CRTC1/MAML2 alone failed to induce MEC formation 
independent of the specific Cre driver allele (Figure 31). These results indicate that 
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oncogene induction specifically affects the ductal cell population but is not sufficient to 
drive MEC tumor formation. 
Given these results, we wanted to generate a cell line that could be manipulated 
in vitro to investigate the ductal cell-specific effects of CRTC1/MAML2 expression. We 
therefore obtained an SV40-immortalized human salivary ductal cell line (Gao et al., 
2014) and engineered it for constitutive overexpression of our LumiFluor bioluminescent 
reporter (PGKLumiFluor) (Schaub et al., 2015) and doxycycline-inducible overexpression of 
either a TdTomato reporter (PTighttdTO) or the CRTC1/MAML2 oncogene (PTightC1/M2) 
(Figure 32A). Validation of the Ductal-PTighttdTO PGKLumiFluor cell line by flow cytometry 
revealed that administration of even 0.1 μg/mL doxycycline potently upregulated 
TdTomato expression (Figures 32B and 32C). Similarly, validation of the Ductal-
PTighttdTO PGKC1/M2 cell line revealed that doxycycline administration induced 
CRTC1/MAML2 overexpression at both the transcript and protein (Figure 32D) levels. 
Finally, luciferase assays demonstrated that CRTC1/MAML2 induction in these cells 
activated the distal PGC-1a promoter (Figure 32E), suggesting that induced expression 
of CRTC1/MAML2 in salivary ductal cells (Ductal-PTighttdTO PGKC1/M2) recapitulates the 
PGC-1a4 – IGF-1 signaling circuit recently described by our lab (Musicant et al., 2021). 
3.2.3 CRTC1/MAML2 Overexpression and TP53 Tumor Suppressor Loss 
Collectively Drive MEC Tumor Formation 
Salivary MECs are generally characterized by a low mutational burden. In fact, 
the recurrent t(11;19) chromosomal translocation characteristic of the majority of 
salivary MECs is often the sole cytogenetic abnormality in these tumors. However, 
recent genomics studies revealed that fusion negative tumors frequently harbor 
mutations that functionally disrupt the tumor suppressor genes TP53 and/or CDKN2A 
 33 
(Jee et al., 2013; Kang et al., 2017; Sheth et al., 2020; Wang et al., 2017). Our own 
RNA sequencing data reveals that CRTC1/MAML2-positive human MEC tumors 
possess functionally wild-type TP53 but are characterized by decreased TP53 gene 
expression and display significantly increased p53 dysregulation (Figure 33), as 
measured using a breast cancer-derived p53 gene signature (Troester et al., 2006). 
Thus, we explored the effects of heterozygous and homozygous TP53 (p53f/+ and p53f/f) 
or CDKN2A (p16f/+ and p16f/f) loss in our K14Cre-C1/M2 transgenic mouse line.  
K14Cre-C1/M2-p16f/+, K14Cre-C1/M2-p16f/f, and K14Cre-C1/M2-p53f/+ animals all 
presented histologically with salivary gland ductal hyperplasia and dysplasia similar to 
that seen in K14Cre-C1/M2 mice but did not develop MEC-like tumors. However, a 
subset of animals with combined CRTC1/MAML2 overexpression and homozygous p53 
loss (K14Cre-C1/M2-p53f/f) formed salivary tumors at approximately 4-5 months following 
tamoxifen administration (Figure 34A). These tumors appeared to originate from the 
submandibular gland (Figures 34B and 34C) and displayed all of the histological 
features characteristic of human salivary MEC (i.e. presence of mucous, epidermoid, 
and intermediate cell types) (Figures 34D and 34E). This indicates that CRTC1/MAML2-
positive salivary MEC arises from a cell population within the salivary duct and that 
murine MEC tumor development depends on both CRTC1/MAML2 expression and p53 
loss.  
3.2.4 Murine Salivary MEC Tumors Recapitulate CRTC1/MAML2-Positive 
Human Salivary MEC Genetics 
 To determine the translational relevance of our GEMM model, we performed 
RNA sequencing on fresh-frozen tissue from each of four murine salivary MEC tumors 
obtained from K14Cre-C1/M2-p53f/f mice. We also sequenced four matched normal 
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submandibular gland tissues from CRTC1/MAML2-negative mice. Gene set enrichment 
analysis (GSEA) revealed that several tumor-supportive pathways, including the 
PI3K/AKT pathway and several metabolic pathways, were altered in the murine MEC 
tumor samples compared with normal tissues (Figure 35). We also wanted to 
investigate whether our previously identified PGC-1a4/IGF-1 signaling axis (Musicant et 
al., 2021) was active in these MEC tumors. Given the difficulties in detecting rare, 
alternatively spliced transcripts such as PGC-1a4 in RNA sequencing data, we instead 
evaluated the ability of our curated Musicant_MEC_CRTC1-MAML2_IGF1 gene list 
(Musicant et al., 2021) to distinguish CRTC1/MAML2-positive murine tumor tissues 
(Figure 36). Our data indicated a remarkable ability of this gene list to differentiate 
between the malignant and non-malignant sample populations.  
Gene expression profiles vary between MEC tumors of different grades (Figure 
37A). Thus, we asked whether the MEC tumors generated in our GEMM more closely 
resembled low, intermediate, or high-grade human MEC tumors. For this analysis, we 
compared RNA sequencing data from the three GEMM tumors with the highest sample 
quality to ten previously sequenced CRTC1/MAML2-positive human MEC tumors 
(Musicant et al., 2021). Correlation scores were assigned based on similarities in gene 
expression profiles between each GEMM sample and the low, intermediate, or high-
grade CRTC1/MAML2-positive human MEC samples, with a score of 1.0 indicating 
perfect correlation. These data indicated that two of the three GEMM tumors more 
closely resembled high-grade human MEC, while the remaining GEMM tumor was most 
similar to low-grade human MEC (Figure 37B). These results indicate that our K14Cre-
C1/M2-p53f/f mouse model faithfully recapitulates several histological and genetic 
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characteristics of human salivary MEC and that we may be able to use this model to 
investigate both low and high-grade MEC. 
3.3 Discussion 
The ability to model oncogenic processes in animals is valuable for a number of 
reasons. GEMMs in particular can provide insight into molecular processes that drive 
tumor initiation, progression, and even metastasis. However, the accurate modeling of a 
particular tumor type requires a working knowledge of the cell of origin of that tumor. 
The cell of origin is a normal cell that acquires a cancer-promoting mutation which is 
then propagated to all daughter cells, forming a tumor (Visvader, 2011). Stem cells are 
often investigated as potential tumor cells of origin due to their innate plasticity and 
capacity for self-renewal. Though several studies have utilized injury models to 
investigate the putative stem and progenitor cell populations in normal salivary glands 
(Emmerson et al., 2017; Holmberg and Hoffman, 2014; Knosp et al., 2012; Kwak et al., 
2016; van Luijk et al., 2015; Maimets et al., 2016; May et al., 2018; Weng et al., 2018), 
no study has yet explored the contributions of these cell types to the development of 
salivary MEC. Therefore, in this study we developed transgenic lines that could 
inducibly express the CRTC1/MAML2 oncogene in each of several different putative 
stem cell populations, including the acinar and intercalated ductal cell populations. Our 
results indicate that CRTC1/MAML2-positive salivary MEC arises in a ductal cell type. 
Here, we have developed a mouse model of MEC that faithfully recapitulates 
both the genetic and the histologic features of disease seen in humans. This GEMM 
was engineered to inducibly express the CRTC1/MAML2 oncogene, which 
characterizes over 50% of human MEC tumors, irrespective of tumor grade (O’Neill, 
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2009; Seethala and Chiosea, 2016; Seethala et al., 2010; Tonon et al., 2003). As MEC 
is frequently characterized by p53 dysregulation, we also engineered our GEMM to 
feature inducible TP53 loss (Jee et al., 2013; Kang et al., 2017; Sheth et al., 2020; 
Wang et al., 2017). Finally, transgene expression in our model was driven by a 
tamoxifen inducible Cre recombinase under the control of a Krt14 promoter. While Krt14 
successfully targets a subset of progenitor cells in the salivary gland ducts, it is also 
expressed in a variety of other epithelial tissues including the oral mucosa, digestive 
tract, and skin (Chu and Weiss, 2002; Su et al., 1993). Thus, our current method of 
activating Krt14-CreERT2 via intraperitoneal injection of tamoxifen also leads to whole-
body transgene activation. While salivary MEC tumors have developed in several 
K14Cre-C1/M2-p53f/f mice, many additional mice of the same genotype reached endpoint 
far before tumor formation due to the appearance of severe off-target effects, including 
oral and skin lesions with significant keratinization (Figures 38A-C). We also stained 
tissues from these animals with mucicarmine to identify the presence of mucous cells 
that could indicate the presence of MEC-like disease. All oral and skin lesions from 
these animals were negative for mucicarmine staining, confirming that these keratinized 
lesions are unlikely to be MEC in origin (Figures 38D-E). 
Future studies will attempt to reduce off-target effects of oncogene induction 
within the cutaneous epithelia through targeted delivery of tamoxifen. Targeted delivery 
may be achieved using several different methods, including trans-dermal injection or 
retroductal cannulation via the Wharton’s duct (Varghese et al., 2018). To test the first 
of these two methods, we performed a pilot study in which we delivered adenovirus 
expressing either Cre recombinase (Ad-Cre) or a GFP control (Ad-GFP) to the 
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submandibular gland via injection directly through the skin. This study was performed in 
animals expressing the LSL-LumiFluor transgene, thus injection of Ad-Cre but not Ad-
GFP should result in expression of the LumiFluor bioluminescent reporter. Our results 
revealed that trans-dermal injections can successfully target the submandibular gland, 
as we observed a bright bioluminescent signal in the salivary region as early as three 
days after Ad-Cre injection (Figure 39). This method is relatively simple to perform and 
would appear to be an ideal method of targeted transgene activation. However, the 
bioluminescent signal seen in mice injected with Ad-Cre faded within two weeks. This 
indicates that the injected Ad-Cre may have induced recombination in a population of 
non-stem/progenitor cells. Following the injury sustained upon transdermal injection, 
regeneration of the gland was therefore achieved by LumiFluor-negative cells and 
bioluminescent signal was lost. The Wharton’s duct cannulation procedure is more 
technically difficult but causes less damage to the salivary glands and thus may result in 
more robust, prolonged transgene activation. This method will be explored in future 
studies.  
The ability to monitor salivary MEC disease progression from pre-neoplastic to 
metastatic disease in a GEMM will allow for the dissection of key genes and signaling 
pathways driving tumor cell proliferation and migration. During development, the 
salivary glands undergo a process called branching morphogenesis, which is mediated 
in part by increased activation of the FGFR and IGF-1R signaling cascades (Amano and 
Iseki, 1993; Hoffman et al., 2002; Kerr et al., 1995; Ryan et al., 1992; Werner and Katz, 
2004). Dysregulation of these growth factor signaling pathways, most notably the IGF-
1R signaling cascade, is associated with multiple cancer types, including salivary gland 
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cancers (Babina and Turner, 2017; Musicant et al., 2021; Pollak, 2008; Yu and Rohan, 
2000). Several studies have indicated that reactivation of stem cell and fetal gene 
expression programs may drive tumorigenesis and may be correlated with increased 
tumor aggressiveness (Ben-Porath et al., 2008; Kim and Orkin, 2011; Spike et al., 
2012). We have recently obtained several RNA sequencing data sets from both human 
and mouse fetal salivary glands and are currently investigating these datasets along 
with our own GEMM and human MEC tumor datasets to determine if a similar fetal gene 
expression program is being reactivated in salivary MEC.   
While further refinement of this newly developed GEMM is required to reduce 
mortality arising from off-target effects, this mouse model provides a much-needed tool 




CHAPTER 4: FUTURE DIRECTIONS IN MUCOEPIDERMOID CARCINOMA 
RESEARCH 
 
The field of mucoepidermoid carcinoma research has made great strides in 
recent years. From transcriptomic sequencing studies (Jee et al., 2013; Kang et al., 
2017; Musicant et al., 2021; Sheth et al., 2020; Wang et al., 2017) to the identification of 
potential therapeutic vulnerabilities (Chen et al., 2014; Musicant et al., 2021; Wagner et 
al., 2018), the abundance of new data has provided hope to those currently battling this 
disease. However, there are a number of topics which remain to be addressed in future 
studies. 
Over half of all MEC cases are characterized by a t(11;19)(q14-21; p12-13) 
chromosomal rearrangement that produces the CRTC1/MAML2 fusion oncogene 
(O’Neill, 2009; Seethala and Chiosea, 2016; Seethala et al., 2010; Tonon et al., 2003). 
The CRTC1/MAML2 protein product has been shown to function as a rogue coactivator 
of a number of transcription factors including CREB, MYC, and AP-1 (Amelio et al., 
2014; Canettieri et al., 2009; Coxon et al., 2005; Wu et al., 2005). Through these 
interactions, CRTC1/MAML2 activates a myriad of tumor-supportive cascades, including 
those acting through EGFR (Chen et al., 2014) and IGF-1R (Musicant et al., 2021), and 
preclinical studies have indicated that therapeutics targeting these pathways may be 
beneficial for the treatment of salivary MEC. However, recent work from our lab has 
revealed that targeting the EGFR pathway specifically does not induce MEC tumor cell 
death (Parag-Sharma et al., 2021). Instead, EGFR inhibitors such as Erlotinib exert 
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cytostatic effects, causing MEC cells to enter a quiescent but viable state that can be 
reversed upon drug withdrawal. Therefore, EGFR inhibitors are not appropriate as 
single-agent MEC therapeutics, as they can halt tumor progression but cannot reduce 
tumor volume. Rather, our recent study demonstrates that combined treatment 
approaches using EGFR inhibitors with a sensitizing agent, such as a histone 
deacetylase (HDAC) inhibitor, is more clinically relevant (Parag-Sharma et al., 2021). 
Similarly, though our lab has revealed that MEC cells are sensitive to IGF-1R inhibition 
(Musicant et al., 2021), preclinical studies have revealed that tumors may develop 
resistance to RTK inhibitors and clinical trials have shown disappointing responses to 
these agents (Chen and Sharon, 2013; Coca-Pelaz et al., 2015; Denduluri et al., 2015; 
McHugh et al., 2012). Therefore, our work suggests that IGF-1R inhibition should be 
replaced by or combined with other targeted therapies, such as PPARγ inverse agonists 
(Musicant et al., 2021). Future molecular studies should focus on dissecting the relative 
importance of individual growth factor signaling cascades in order to identify those most 
promising for therapeutic targeting. 
Early studies that identified the CRTC1/MAML2 fusion in human tumor samples 
correlated fusion status with tumor grade. Specifically, the CRTC1/MAML2 fusion was 
identified more frequently in low grade tumors and was correlated with improved 
prognosis (O’Neill, 2009). However, improved MEC grading systems have revealed that 
many tumors originally characterized as high grade, fusion-positive MEC are not MEC 
at all. Instead, these tumors are often reclassified as adenosquamous or salivary duct 
carcinomas (Chenevert et al., 2011; Chiosea et al., 2012; Seethala et al., 2010; Tirado 
et al., 2007). Subsequent reanalysis of CRTC1/MAML2 positivity rates in low, 
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intermediate, and high grade MEC indicate that the fusion event occurs at roughly equal 
rates in all tumor grades and is not correlated with disease outcome (Cipriani et al., 
2019b; Saade et al., 2016; Seethala and Chiosea, 2016). However, it is unclear whether 
the downstream pathways affected by CRTC1/MAML2 are differentially regulated in 
various MEC grades. For example, are MYC-regulated stemness or apoptosis pathways 
dysregulated more frequently in high grade tumors? Or are CREB-regulated 
proliferation- and differentiation-associated pathways dysregulated more frequently in 
low grade tumors? Future studies should explore differential gene expression programs 
in relation to tumor grade. The findings from such analyses could be informative when 
considering an individual’s prognosis and treatment options. 
On a broader level, it is interesting to note that in all fusion-positive MEC 
patients, the breakpoints producing the CRTC1/MAML2 fusion oncogene are nearly 
identical at the genome level and indistinguishable at the protein level. While many 
studies have explored the impact of this translocation on cellular function and tumor 
progression, few studies have investigated the mechanisms that contribute to this 
specific genomic alteration. The limited investigations into susceptibility to chromosomal 
rearrangements have largely been performed in the context of hematological 
malignancies. These studies have suggested that most translocations occur due to 
erroneous repair of double-strand breaks (DSBs) via non-homologous end joining 
(NHEJ) (Boehm et al., 1989; Lin and Scott, 2012; Novo and Vizmanos, 2006; Obe et al., 
2002; Povirk, 2006). Additionally, these studies have indicated that DSBs and aberrant 
NHEJ are more likely to occur in regions of active transcription or increased chromatin 
accessibility (Mitelman et al., 2019). However, there are currently no studies in which 
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these hypotheses have been tested in the context of the t(11;19) translocation observed 
in MEC. 
Finally, it will be important to focus future efforts on refining the GEMM described 
in Chapter 3. Whole-body oncogene activation in our K14Cre-C1/M2-p53f/f mouse model 
resulted in significant off-target effects within the cutaneous epithelia. To reduce these 
effects, we propose the targeted delivery of tamoxifen via either trans-dermal injection 
into the submandibular gland or ductal cannulation via the Wharton’s duct (Varghese et 
al., 2018). Our pilot study investigating the feasibility of the former method 
demonstrated successful targeting of the submandibular gland but short-lived 
recombination. The Wharton’s duct cannulation procedure is currently being explored in 
our lab but is quite technically difficult and will require a significant investment in terms 
of person hours. Despite these challenges, successful targeted tamoxifen delivery 
would deliver a substantial reward. A reliable mouse model that recapitulates both the 
genetic and microenvironmental features of human MEC would allow for the testing of 
novel therapeutics and would allow for exciting investigations into all stages of tumor 




APPENDIX 1: MATERIALS AND METHODS 
 
Clinical samples 
All research involving human tumor tissues was reviewed and approved by The 
University of North Carolina at Chapel Hill Institutional Review Board under IRB 
protocols 15-1604 and 17-2947. Tissues from these de-identified clinical subjects were 
identified from chart review and archived formalin-fixed paraffin-embedded (FFPE) 
salivary MEC (n = 18; 10 females and 8 males, average age of 49.6 yrs) or normal 
salivary gland (n = 6) tissue samples stored at room temperature less than ten years 
before blocks were sectioned and RNA isolation performed. For all cases, multiple H&E 
slides were reviewed by a pathologist and sections with tumor were selected for 
inclusion in the study. Adjacent serial unstained sections were then macrodissected and 
tumor material submitted for RNA extraction. 
Animal models 
All animal studies were reviewed and approved by The University of North 
Carolina at Chapel Hill Institutional Animal Care and Use Committee under IACUC 
protocols 17-202 and 20-242. For xenograft studies, male 6-8 week old athymic nude 
mice (Nu/Nu) were obtained from the Animal Studies Core at the University of North 
Carolina at Chapel Hill and housed in facilities run by the Division of Comparative 
Medicine at the University of North Carolina (Chapel Hill, NC, USA).  
Xenografts 
For all xenograft studies, mice were subcutaneously injected with 1x106 UM-
HMC-3A cells resuspended in 50% HBSS and 50% Matrigel. When the average tumor 
size reached a palpable volume (~50 mm3), animals were randomized into two groups 
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(Vehicle and SR10221 or SR2595) so that the average tumor size in each group was 
approximately equal. The vehicle group was intraperitoneally (i.p.) injected daily with 
250 µL of a 10% DMSO, 10% Tween-80, 80% PBS solution. Drug-treated animals were 
i.p. injected daily with a 10% DMSO, 10% Tween-80, 80% PBS solution containing 
either 20 mg/kg SR10221 or 60 mg/kg SR2595 (Sigma-Aldrich #SML2037) based on an 
average mouse weight of 25g. Caliper measurements were collected every 2 days and 
bioluminescent imaging (BLI) was performed every 5 days throughout the course of the 
study. 
Genetically engineered mice 
Dcpp1GCE (MGI:5661581; referred to here as DcppCre) (Maruyama et al., 2016) 
and MistCre mouse strains were generously provided by Dr. Catherine Ovitt (University 
of Rochester). K14CreERT (referred to here as K14Cre) mice were obtained from The 
Jackson Laboratory (Stock #005107). LSL-CRTC1/MAML2 (referred to here as C1/M2) 
mice were generously provided by Dr. Lizi Wu (University of Florida). Rosa26-LSL-
GpNLuc mice were generated by knocking in the GpNLuc (Schaub et al., 2015) 
LumiFluor optical reporter cDNA as described in (Carper et al., 2019). Trp53 floxed 
mice were obtained from the National Cancer Institute Mouse Repository (Strain 
#01XC2). p16 floxed mice were a generous gift from Dr. Bernard Weissman (UNC 
Chapel Hill). All animals were backcrossed to C57BL/6J or albino B6(Cg)-Tyrc-2J/J mice 
(The Jackson Laboratory, Stock #: 000664 or Stock #: 000058) for 7-10 generations. 
DcppCre and MistCre alleles were maintained at heterozygosity; all other alleles were 
bred to either heterozygosity or homozygosity. 
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Tamoxifen (Sigma-Aldrich #T5648) was dissolved at 10 mg/mL in corn oil (MP 
Biomedical #901414). To conditionally induce Cre recombinase activation, 8-week old 
male and female animals were i.p. injected with 100 µL tamoxifen once a day for five 
days.  
For transdermal adenovirus injections, 8-week old animals were injected with 107 
IU adenovirus expressing either Cre recombinase or GFP. Adenovirus was brought to 
50 µl total volume in PBS and injected transdermally into the submandibular gland using 
a 29.5-gauge needle once every other day for a total of three injections. 
Cell lines 
UM-HMC-1 (HMC1), UM-HMC-3A (HMC3A), and UM-HMC-3B (HMC3B) cells 
(Warner et al., 2013) were kindly provided by Dr. Jacques Nör (University of Michigan, 
Ann Arbor, MI, USA). NCI-H292 (H292) and NCI-H3118 (H3118) cells (Tonon et al., 
2003) were generously provided by Dr. Frederic Kaye (University of Florida, Gainesville, 
FL, USA). A253, A388, and A431 cells were kindly provided by Dr. Bernard Weissman 
(University of North Carolina, Chapel Hill, NC, USA). HMC1 (source: male, salivary 
gland MEC), HMC3A (source: female, hard palate MEC), and HMC3B (source: female, 
lymph node metastasis of hard palate MEC) parental and stably transduced lines were 
cultured in DMEM medium (Gibco #11965-118) supplemented with 10% FBS (Atlanta 
Biologicals #S11550), 20 ng/mL EGF (Sigma-Aldrich #E9644), 400 ng/mL 
hydrocortisone (Sigma-Aldrich #H0888), 5 µg/mL insulin (Sigma-Aldrich #I6634), and 
1X pen/strep/glutamine (PSG; Life Tech #10378016). H292 (source: female, lung MEC) 
cells were cultured in RPMI-1640 medium (Life Tech #11875119) supplemented with 
10% FBS, 1X GlutaMAX (Life Tech #35050061), 1X NEAA (Gibco #11140050), 1X 
 46 
NaPyr (Life Tech #11360070), and 1X PSG. HEK293A, HEK293-CMVTetRTetOC1/M2 
(Amelio et al., 2014), HEK293-PGKTetOn3GTRE3GSPGC-1α4, Lenti X-293T (viral packaging 
cell line; Takara #632180), H3118 (source: female, parotid gland MEC), A388 (source: 
male, squamous cell carcinoma (SCC)), and A431 (source: female, vulvar SCC) cells 
were cultured in DMEM supplemented with 10% FBS, 1X GlutaMAX, and 1X PSG. 
A253 (source: male, salivary gland SCC) cells were cultured in McCoy’s 5A medium 
(Life Tech #16600108) supplemented with 10% FBS, 1X GlutaMAX, and 1X PSG. Cells 
were passaged using TrypLE (Gibco #12604013) every 2-3 days or when they reached 
90% confluence. All cells were maintained in a 37°C, 5% CO2 atmosphere. All cell lines 
were confirmed mycoplasma-free by PCR as previously described (Young et al., 2010) 
and using mycoplasma detection primers (Table 5). 
Clinical RNA isolation 
FFPE tissue samples were sent to the UNC Lineberger Comprehensive Cancer 
Center Translational Genomics Lab (TGL) for RNA isolation using the Maxwell 16 MDx 
Instrument (Promega #AS3000) and the Maxwell 16 LEV RNA FFPE Kit (Promega 
#AS1260) according to the manufacturer’s protocol (Promega #9FB167). Pathology 
review of a hematoxylin and eosin (H&E) stained slide was used to guide macro-
dissection of unstained slides to enrich for tumor RNA. Total RNA quality was measured 
using a NanoDrop spectrophotometer (Thermo Scientific ND-2000C) and a TapeStation 
4200 (Agilent G2991AA). Total RNA concentration was quantified using a Qubit 3.0 





Total RNA sequencing libraries were prepared at TGL using a Bravo Automated 
Liquid-Handling Platform (Agilent G5562A) and the TruSeq Stranded Total RNA Library 
Prep Gold Kit (Illumina 20020599) according to the manufacturer’s protocol (Illumina 
1000000040499). RNAseq library quality and quantity were measured using a 
TapeStation 4200 (Agilent G2991AA), pooled at equal molar ratios, and denatured 
according to the manufacturer’s protocol (Illumina 15050107). Sequencing was 
performed at the High Throughput Sequencing Facility (HTSF) at UNC Chapel Hill. Two 
RNA-seq libraries were sequenced per lane on a HiSeq2500 (Illumina SY–401–2501) 
with 2x50 bp paired-end configuration according to the manufacturer’s protocol (Illumina 
15035786). 
Bioinformatics 
RNAseq data analyses were performed with FASTQ files aligned to the GRCh38 
human genome (GRCh38.d1.vd1.fa) or the GRCm38 mouse genome using STAR 
v2.4.2 (Dobin et al., 2013) with the following parameters: --outSAMtype BAM Unsorted, 
--quantMode TranscriptomeSAM. Transcript abundance for each sample was estimated 
using Salmon version 0.1.19 (Patro et al., 2017) to quantify the transcriptome defined by 
Gencode v22. Gene level counts were summed across isoforms and genes with low 
expression (i.e. samples with fewer than 10 reads) were removed prior to downstream 
analyses. The R package DESeq2 (version 1.24.0) (Love et al., 2014) was used to test 
for differentially expressed genes between CRTC1/MAML2-positive MEC tumors and 
normal samples or between all MEC tumors and normal samples. The CRTC1/MAML2-
regulated IGF-PI3K gene signature (Musicant_MEC_CRTC1-MAML2_IGF1 curated 
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gene set) includes genes that are differentially expressed between CRTC1/MAML2-
positive MEC samples and normal samples with Benjamini–Hochberg false discovery 
rate (q-value) < 0.05 and a fold change > 2. The resulting list of genes was refined to 
include only genes shared with IGF1-related Molecular Signatures Database (MSigDB) 
curated gene sets. Gene set enrichment analysis was performed on a customized list of 
gene sets with GSEA software from the Broad Institute (Mootha et al., 2003; 
Subramanian et al., 2005). The customized gene sets include a list of pathways from 
MSigDB curated gene sets that are related to IGF1. Hierarchical clustering and heat-
map plotting were performed using the ComplexHeatmap R package version 2.0.0 (Gu 
et al., 2016). An average linkage algorithm with a Euclidean distance function was 
applied to variance stabilizing transformed gene expression data for the gene signature. 
RTKi drug screen 
Compound screening was performed as previously described (Bevill et al., 2019; 
Lipner et al., 2020). Briefly, drug screening was performed in a 384 well plate format, in 
duplicate. Cells were seeded in 45 µL of full culture media; A253 (1000 cells/well), H292 
(600 cells/well) H3118 (7000 cells/well), HMC1 (500 cells/well), HMC3A (500 cells/well) 
and HMC3B (700 cells/well). Cells were seeded in 384-well plates using a BioTek 
microplate dispenser. Cells were allowed to adhere overnight, following which they were 
treated with 176 individual drugs at 6 doses (10 nM, 100 nM, 300 nM, 1 µM, 3 µM and 
10 µM) using a Beckman Coulter Biomek FX Automated Liquid Handling instrument. 
Each plate also included 1 µM Bortezomib and 1% DMSO as positive and negative 
controls for growth inhibition, respectively. Furthermore, a full 384 well plate with 1% 
DMSO treatment was also seeded per cell line and was used to confirm minimal well-
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location associated intra-plate variability. 72 hr post drug addition, cells were lysed, and 
cell viability was measured using Cell Titer Glo 2.0 (Promega #G9243) according to the 
manufacturer’s instructions. Luminescence was measured using a PHERAstar FS 
instrument and growth inhibition was calculated relative to DMSO-treated wells. Z’ 
scores were calculated as previously described (Zhang et al., 1999). The 1 µM 
Bortezomib (positive control; 0% viability) and 1% DMSO (negative control; 100% 
viability)-treated cells were used to calculate the dynamic range and screen 
variability/reliability (Z’ score). A Z’ score of >0.75 was obtained for all cell lines tested. 
The 3SD/5SD cutoffs were calculated based on the variability observed in the negative 
control wells. 
Virus production and transduction 
Lentiviral or retroviral expression plasmids were co-transfected with VSV-G 
envelope plasmid and either δ8.2 gag/pol (lentivirus) or pMD (retrovirus) helper 
plasmids into Lenti X-293T cells seeded in 10 cm tissue culture dishes. Transfections 
were performed using 1 mg/mL Polyethyleneimine (PEI) Transfection Reagent (VWR 
#BT129700). Briefly, 1.5 µg VSV-G, 5 µg δ8.2 or pMD, and 6 µg lentiviral or retroviral 
plasmid were brought to 500 µL with OptiMEM (LifeTech #1158021) and vortexed 
briefly. In a separate tube, 25 µL PEI (2 µL PEI/µg DNA) was added to 475 µL OptiMEM 
and vortexed briefly. Both solutions were incubated at room temperature for 5 min, then 
combined and incubated for an additional 20 min at room temperature. This mixture was 
then added dropwise to the seeded Lenti X-293T cells. The next day, cell culture media 
was replaced with DMEM supplemented with 1x NaPyr, 10 mM HEPES, 1X GlutaMAX, 
and 1X PSG (no FBS). Two days later, media was collected and filtered through a 0.45 
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µm PVDF membrane and then viral particles were concentrated via ultracentrifugation 
(100,000 g for 2 hr at 4°C) into a sucrose cushion. Concentrated virus was resuspended 
in cold PBS and either stored at -80°C or used immediately for transduction. 
To generate stable cells, various cell lines were seeded at 50% confluency in 12-
well plates. Concentrated virus and 4 µg/mL polybrene were added directly to cells and 
then plates were centrifuged at 1200g for 90 min at 30°C. To generate stable 
LumiFluor-overexpressing cells, HMC3A cells were transduced with concentrated 
lentivirus expressing our GpNLuc reporter (Schaub et al., 2015) and selected with 
puromycin for at least 10 days prior to use in experiments. To generate stable Ductal 
cells with inducible TdTomato or CRTC1/MAML2 expression, SV-40 immortalized 
salivary ductal cells (Gao et al., 2014) were transduced with concentrated retrovirus 
encoding either PTightdTOPGKLumiFluor or PTightC1/M2PGKLumiFluor and stable cells were 
selected by fluorescence activated cell sorting (FACS) by gating for GpNLuc-positive 
cells. To generate shRNA-expressing cells, parental HMC3A or HMC3A-PGKGpNLuc cells 
were transduced with concentrated shRNA-expressing retro- or lentivirus expressing the 
shRNA of interest. Proliferation assays, quantitative real-time PCR, and Western 
blotting were performed on polyclonal cell populations within 14 days of transduction for 
all shRNA knockdown experiments. To generate cells that express the PGC-1α4 splice 
variant, HEK293A cells were first transduced with a concentrated lentivirus that 
expresses TetOn3G and stable cells selected with puromycin. Subsequently, these 
HEK293-PGKTetOn3G stables were transduced with a concentrated lentivirus that 
expresses PGC-1α4 upon tetracycline/doxycycline administration and the resulting 
HEK293-PGKTetOn3G-TRE3GSPGC-1α4 stable cells were selected with hygromycin for at 
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least 10 days prior to use in experiments. To generate MEC cells with inducible 
dominant-negative CREB (dnCREB; A-CREB), HMC3A cells were first transduced with 
a concentrated lentivirus that expresses TetOn3G and stable cells were selected with 
puromycin. These HMC3A-PGKTetOn3G stables were transduced with a concentrated 
retrovirus that expresses A-CREB (Ahn et al., 1998) upon tetracycline/doxycycline 
administration, and the resulting HMC3A-PGKTetOn3G-TetOdnCREB stable cells were 
selected by FACS by gating for tdTomato-positive cells. To generate MEC cells with 
inducible dCas9 expression, HMC3A cells were first transduced with a concentrated 
lentivirus that expresses TetOn3G and stable cells were selected with puromycin. 
These HMC3A-PGKTetOn3G stables were transduced with a concentrated lentivirus 
encoding the doxycycline induced dCas9-KRAB-IRES-BFP cassette (Addgene #85449) 
(Fulco et al., 2016). To select for positively transduced cells, 1 μg/mL doxycycline was 
applied to the cells for 72 hours and then BFP-positive cells were selected by FACS. 
Finally, the HMC3A-PGKTetOn3G -TRE3GSdCas9-KRAB-IRES-BFP cells were transduced with a 
lentivirus constitutively expressing the respective PGC-1α sgRNA, a blasticidin 
resistance cassette, and a 2xNLS-mKate2 fluorescent reporter. Cells were selected with 
blasticidin for at least 7 days and successful selection was confirmed via nuclear 
mKate2 fluorescence signal. 
Cell viability  
HMC1, HMC3A, or HMC3B cells were seeded in 96-well clear-bottom, white-
walled plates (Corning #3917) at 15,000 cells/well. The next day, media was replaced 
with 200 μL fresh media containing either vehicle (DMSO) or increasing concentrations 
of drug (BMS-754807 (Sigma-Aldrich #BM0003), PPP (Santa Cruz #SC-204008), 
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SR10221 (synthesis detailed in Musicant et al., 2021), SR2595 (Sigma-Aldrich 
#SML2037), or T0070907 (Fisher #NC1015539); final concentration 1% DMSO). 72 hr 
later, the amount of ATP (a proxy for cell viability) in each well was measured using the 
ATPlite Luminescence Assay System (PerkinElmer #6016949) according to the 
manufacturer’s instructions. Briefly, plates were removed from the cell culture incubator 
and equilibrated for 30 min at room temperature in the dark. Then, media was aspirated 
from each well and 100 μL reconstituted ATPlite 1-step reagent was added to each well. 
Plates were shaken for 2 min (425 cpm, 3 mm orbit) in a Cytation 5 plate reader (BioTek 
Instruments, Inc.) and then ATP levels were quantified by measuring total 
luminescence. IC50 values were calculated in GraphPad Prism (GraphPad, San Diego, 
CA, USA) using a non-linear curve fit (log[agonist] vs response, four parameter-variable 
slope). All assays were performed in biologic triplicate with three technical replicates for 
each condition. Figure panels show one representative experiment (including three 
technical replicates each). IC50 values presented in Table 2 were calculated using the 
results from all three biologic replicates. 
Cell proliferation assays (Cytation 5) 
HMC3A-PGKGpNLuc cells (either non-transduced or transduced with shRNAs 
targeting PGC-1α, IGF-1R, or MAML2) were seeded in 12-well plates at 200,000 
cells/well. The next day, fresh media was applied to each well and then individual wells 
were imaged at 0, 4, 8, 24, 28, 32, and 48 hr following the media change. Five separate 
fields of view were imaged for each well at 4X magnification using a fluorescent plate 
reader (BioTek Cytation 5, BioTek Instruments, Inc.). Between each imaging time point, 
plates were returned to the cell culture incubator. To determine cell confluence, a 
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primary mask was applied to each fluorescent image using the recommended 
parameters set out in the BioTek Technical Note “Measuring Confluence Using High 
Contrast Brightfield” (https://www.biotek.com/resources/technical-notes/measuring-
confluence-using-high-contrast-brightfield/). Confluence measurements from multiple 
fields of view in a single well were used as technical replicates. Each assay was 
performed in biologic triplicate. 
Cell proliferation assays (IncuCyte Zoom) 
HMC3A cells were seeded in 48-well plates at 15,000 cells/well. The next day, 
media was replaced with fresh media containing either vehicle (1% DMSO) or the 
indicated concentration of PPP (Santa Cruz #SC-204008) or SR10221. Then, plates 
were imaged at 10X magnification every 2-4 hours on an IncuCyte Zoom (Essen 
BioScience), which maintained plates at a constant 37°C and 5% CO2 for the duration 
of the assay. Four separate fields of view were imaged for each well and an image 
mask was applied to each image to generate confluency measurements. Each assay 
was performed in biologic triplicate with at least three technical replicates per 
experiment. 
Western blotting 
Whole cell lysates were prepared in buffer containing 5% glycerol (Sigma-Aldrich 
#G5516), 25 mM Tris (pH 7.4; Fisher #BMA51237), 150 mM NaCl (Fisher #BMA51202), 
1 mM EDTA (Sigma-Aldrich #E7889), and 1% NP-40 (Fisher #50-147-289) 
supplemented with protease inhibitors (cOmplete, EDTA-free Protease Inhibitor 
Cocktail, Roche #04693132001) and phosphatase inhibitors (PhosSTOP, Roche 
#10917400). Lysates (30-50 mg) were loaded onto mini-10% tris-glycine polyacrylamide 
 54 
gels and proteins were separated using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Proteins were transferred to a 0.45 μm nitrocellulose 
membrane (Fisher #0088018) using a Bio-Rad Trans-Blot Turbo system set at 1.3 
Amps (constant) and 25 V for 30 min. Membranes were blocked for 1 hr at room 
temperature in TBS-T + 5% bovine serum albumin (BSA; Sigma #A2153) and then 
incubated overnight at 4°C with primary antibodies: IGF-1 (0.2 μg/mL; Abcam #ab9572), 
IGF-1Rβ (1:2500; Cell Signaling #3018S), phosphorylated IGF-1Rβ (Tyr1135; 1:1000; 
Cell Signaling #3918S), PPARγ (1:1000; Abcam #209350), actin (1:5000; Sigma 
#A3854), tubulin (1:5000; Sigma #T6074), or Flag (1:5000; Sigma #A8592) diluted in 
TBS-T + 5% BSA. Following primary antibody incubation, membranes were washed and 
probed with Horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:5000; 
Thermo Fisher #31432) or donkey anti-rabbit (1:5000; Thermo Fisher #31458) 
secondary antibodies diluted in TBS-T supplemented with 5% BSA for 1-2 hr at room 
temperature. Blots were imaged using Clarity ECL (Bio-Rad #170-5060) and 
ImageQuant LHS4000 (GE). 
2D colony formation 
HMC1, HMC3A, and HMC3B cells were seeded in 24-well plates at 800, 600, 
and 1400 cells/well, respectively. The next day, media was replaced with 500 μL fresh 
media containing either vehicle (DMSO) or the indicated concentration of drug (BMS-
754807 (Sigma-Aldrich #BM0003), PPP (Santa Cruz #SC-204008), SR10221, SR2595 
(Sigma-Aldrich #SML2037), or T0070907 (Fisher #NC1015539); final concentration 1% 
DMSO). Seven days later, media was removed from all wells and cells were fixed in 
10% buffered formalin (Fisher #SF994) for 5 min at room temperature. Wells were 
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washed once in ddH2O and then stained in 0.05% crystal violet (Sigma-Aldrich #C6158) 
for 30 min at room temperature. Wells were then washed an additional 3 times in ddH2O 
to remove any unbound stain and allowed to dry at room temperature overnight. Once 
dry, individual wells were imaged at 4X magnification on a BioTek Cytation 5 plate 
reader (BioTek Instruments, Inc.) and images were stitched using the Gen5 software 
(v2.09; BioTek Instruments, Inc.) using the default parameters. Colony numbers were 
quantified manually in Image J (Schneider et al., 2012), where a colony is defined as a 
cluster of at least 50 individual cells. 
3D tumor spheroid formation 
Individual wells of a 48-well plate were coated with 100 μL of a 25% Matrigel 
(Fisher #CB4023A) solution diluted in cold PBS. The plate was spun in a Thermo 
Scientific Sorvall LYNX 4000 centrifuge at 4°C for 10 min at 2000g to ensure even 
distribution across the well surface. The plate was then placed in a 37°C incubator for 1 
hr to allow the Matrigel ‘bed’ to completely polymerize. Next, excess PBS was gently 
aspirated from the wells and 2000 HMC3A cells resuspended in 100 μL media were 
added to each well. The plate was centrifuged at 4°C for 5 min at 2000g to embed the 
cells into the Matrigel. The plate was returned to the incubator for an additional hour to 
allow for cell adhesion to the Matrigel. After 1 hr, excess media was carefully aspirated 
and 50 μL undiluted Matrigel was gently added to each well on top of the cells. The 
plate was again returned to the incubator for 1 hr to allow for Matrigel polymerization. 
Finally, 500 μL media (containing either drug or vehicle at a final concentration of 1% 
DMSO) was added to each well. Every 24 hr, wells were imaged at 4X magnification on 
a BioTek Cytation 5 plate reader (BioTek Instruments, Inc.) and images were stitched 
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using the Gen5 software (v2.09; BioTek Instruments, Inc.) using the default parameters. 
Tumorsphere area was manually measured in ImageJ using the ROI area measurement 
tool. A minimum of 50 individual tumorspheres were quantified for each condition in 
each experiment. 
Caspase 3/7 apoptosis assay 
For drug treatment assays, HMC3A cells were seeded in 6-well plates at 350,000 
cells/well. The next day, media was replaced with 2 mL fresh media containing either 
vehicle (DMSO) or the indicated concentration of drug (PPP (Santa Cruz #SC-204008) 
or SR10221; final concentration 1% DMSO). For shRNA assays, HMC3A cells stably 
transduced with shNS (control) or shPPARγ were seeded in 6-well plates at 350,000 
cells/well. At the indicated time point (either post-treatment (PPP/SR10221) or post-
seeding (shRNAs)), cells were trypsinized, spun down, and resuspended in 1 mL PBS 
supplemented with 1X GlutaMAX (Life Tech #35050061) and 10% FBS (Atlanta 
Biologicals #S11550). Apoptotic cells were visualized using the CellEvent Caspase 3/7 
Green Flow Cytometry Assay Kit (ThermoFisher #C10427) according to the 
manufacturer’s instructions. Briefly, 1 μL CellEvent Caspase 3/7 Green Detection 
Reagent was added per 1 mL of resuspended cells. This mixture was gently vortexed 
and incubated at 37°C for 25 min. Next, 1 μL SYTOX AADvanced Dead Cell Stain was 
added per 1 mL of resuspended cells. This mixture was gently vortexed and incubated 
at 37°C for an additional 5 min. Samples were analyzed via flow cytometry on a BD 
Accuri C6 instrument. An aliquot of unstained cells from each condition was reserved as 
a control to generate gates. 
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Chromatin immunoprecipitation (ChIP) assay 
HEK293-CMVTetRTetOC1/M2 cells (Amelio et al., 2014) were seeded in 15 cm 
tissue culture dishes in either plain growth medium or growth medium containing 1 
μg/mL doxycycline (Sigma-Aldrich #D9891). After 48 hr, formaldehyde (Fisher #BP531) 
was added dropwise to each plate to 1% final concentration. Plates were incubated at 
room temperature for 10 min and then crosslinking was stopped by adding glycine 
(Fisher #BP381-1) to a final concentration of 120 mM and incubating for an additional 5 
min. Cells were then transferred to a tube, pelleted at 4°C, and washed twice with cold 
PBS. Finally, washed cells were resuspended in PBS supplemented with protease 
inhibitors (cOmplete, EDTA-free Protease Inhibitor Cocktail, Roche #04693132001) to a 
concentration of 5x106 cells/mL and stored at -80°C in aliquots of 1 mL until lysis. For 
lysis, individual cell aliquots were pelleted, resuspended in 200 μL SDS lysis buffer (1% 
SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1) supplemented with protease inhibitors, 
and rocked at 4°C for at least 20 min. Next, 800 μL ChIP dilution buffer was added and 
aliquots were immersed in a 100% ethanol ice bath (-11 to -7°C) and sheared (2 Amp 
for 5 seconds) using a sonicator (Qsonica #Q700A) equipped with a microtip sonic 
dismembrator (Model 505, Fisher #4418). A fraction of this sheared sample was 
reserved as a Pre-IP control. To the rest of the sample, 1 μg anti-Flag M2 antibody 
(Sigma #F1804) was added and samples were rocked at 4°C overnight. Antibody-
chromatin complexes were isolated by rocking with Protein G SureBeads (BioRad 
#1614821) at 4°C for 4 hr. Beads were washed once each in low salt buffer (0.1% SDS, 
1% TritonX-100, 2 mM EDTA, 20 mM Tris-HCl, 15 mM NaCl), high salt buffer (0.1% 
SDS, 1% TritonX-100, 2 mM EDTA, 20 mM Tris-HCl, 500 mM NaCl), and LiCl buffer 
 58 
(250 mM LiCl, 1% NP-40, 1% Deoxycholate, 1mM EDTA, 10 mM Tris-HCl, pH 8.1) and 
then twice in TE buffer (1.2 mM EDTA, 10 mM Tris-HCl, pH 8.1). Samples were eluted 
twice with pre-heated (55°C) elution buffer for 15 min at room temperature with shaking. 
Cross-links were reversed by adding NaCl to 200 mM and incubating for at least 4 hr at 
65°C. Samples were treated for 30 min at 37°C with RNase A at 8 μg/μL final 
concentration. Finally, samples were treated with Proteinase K solution (10 μL 0.5 M 
EDTA, 10 μL 1M Tris, 1 μL 20 mg/mL Proteinase K (LifeTech #AM2546) for a 500 μL 
sample) for 1 hr at 50 °C and then DNA was purified using the NucleoSpin Gel and PCR 
Cleanup Kit (Macherey-Nagel #740609.250). Occupancy of target proteins of interest 
within the promoter regions was assessed by qPCR (Table 5). 
Luciferase reporter assay 
HEK293-CMVTetRTetOC1/M2 cells were seeded in 24-well plates at 100,000 
cells/well. The next day, transfected each well with 500 ng of either PGC-1a proximal 
promoter or PGC-1a distal promoter driven luciferase reporter using Lipofectamine 
(Invitrogen #50470) according to the manufacturer’s protocol and using a DNA:lipid ratio 
of 1:2. The next day, media was replaced with 1 mL fresh media with or without 1 μg/mL 
doxycycline (Sigma-Aldrich #D9891). After 24 hr, media was removed from all wells and 
100 μL 1% Triton X-100 was added to each well. Plates were rocked for 15 min at room 
temperature. 50 μL of the supernatant from each well was transferred to a white, 
opaque 96-well plate, and 50 μL Bright-Glo Luciferase Assay Buffer (Promega #E264B) 
was added to each well. Total luminescence was quantified immediately on a BioTek 
Cytation 5 plate reader (BioTek Instruments, Inc.). For the dose-response luciferase 
reporter assays, HEK293 cells were reverse transfected with 3xPPRE promoter or 
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IGF1-P2 promoter driven luciferase reporters using Lipofectamine 2000 Transfection 
Reagent (Invitrogen #11668019) in 96-well plates at a density of 2x104 cells/well. Forty-
eight hours post-transfection, cells were treated with either vehicle (DMSO) or the 
PPARγ ligands GW1929 (Sigma-Aldrich #5668), SR2595 or SR10221 at the indicated 
concentrations. 24 hr after treatment, cells were lysed, and luciferase activity was 
quantified using the Dual-Glo Luciferase Assay System (Promega #E2920). 
Luminescence was measured using Synergy Neo microplate reader (BioTek). Values 
were normalized using Renilla expression. 
Bioluminescence imaging 
Bioluminescent-fluorescent BRET signal was measured non-invasively as 
previously described (Schaub et al., 2015) with minor modification. Briefly, animals were 
i.p. injected with 250 μM (1:20 dilution, ∼500 μg/kg) Nano-Glo Luciferase Assay 
Substrate (Promega, #N1120) in sterile PBS. Isoflurane-anesthetized animals were then 
imaged using an AMI Optical Imaging System (Spectral Instruments Imaging, Inc.) 5 
min after injection. Images were captured with open filter and acquisition times of 5 min 
or less at the indicated settings. Data were analyzed using Aura imaging software 
(v2.2.0.0). 
Histology and immunohistochemistry 
All animals showing tumors > 2 cm3 or other signs of distress were euthanized 
and subjected to full necropsy. For histological analysis, xenograft tumors were fixed in 
10% neutral buffered formalin for approximately 1 week at room temperature. Following 
fixation, tissues were processed on an ASP6025 automated tissue processor (Leica 
Biosystems) and embedded in paraffin wax. Blocks were sectioned at 4-6 μm, mounted 
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on glass slides, and FFPE tissue sections were deparaffinized prior to hematoxylin and 
eosin (H&E) or mucicarmine staining. Immunohistochemistry was performed on the 
Discovery Ultra (Ventana Medical Systems) using manufacturers reagents on 4 μm 
sections. For anti-IGF-1 immunohistochemistry, anti-rabbit IGF-1 (Abcam #ab9572) was 
prepared using Discovery PSS Diluent (cat. #: 760-212). Antigen retrieval was 
performed using Ventana’s CC1 (pH 8.5) for 64 min at 90 °C. The slides were given a 
hydrogen peroxide block for 8 min at room temperature and then incubated in the 
primary antibody diluent (1:100) for 1 hr at room temperature, followed by anti-Rabbit 
HRP secondary antibody (Vector Labs #MP-7401) for 32 min at room temperature. The 
slides were then treated with DAB and counterstained with Hematoxylin II for 12 min 
and then Bluing Reagent for 4 min. 
Plasmids 
 The PGC-1a promoter constructs were generated by cloning the -500 to +52 bp 
of either the proximal or distal human PGC-1a promoter sequences via 5’ NheI and 3’ 
HindIII into the pGL4.15 luciferase reporter (Promega #E6701). The human IGF-1 
promoter constructs were generated by cloning either a 2079 bp region encompassing 
the P1 promoter or a 1547 bp region encompassing the P2 promoter via 5’ BglII and 3’ 
HindIII into either the pGL4.15 (Promega #E6701) or the pGL3-Enhancer luciferase 
reporter (Promega #E1771). The A-CREB (Ahn et al., 1998) dominant-negative CREB 
cDNA was directionally cloned via 5′ NotI and 3′ MluI restriction enzyme sites into 
pRetroX-Tight-tdTomato (Amelio et al., 2014). The pTRE3G-MCS_PGK-GpNLuc 
construct was generated by excising the pTight promoter from the pRetroX-Tight-
MCS_PGK-GpNLuc construct (Addgene plasmid #70185) containing our previously 
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described LumiFluor optical reporter (Schaub et al., 2015) and subcloning the TRE3G 
promoter in its place. Subsequently, a N-terminal FLAG-tagged CRTC1/MAML2 cDNA 
was directionally subcloned via 5’ NotI and 3’ MluI restriction enzyme sites into this 
pTRE3G-MCS-GpNLuc vector. The pLV-TRE3G_PGC1a4-mCherry:T2A:Hygro 
construct was custom synthesized (Cyagen Bioscience) to contain the human 
PPARGC1A variant 4 splice isoform (PGC-1a4) (Ruas et al., 2012) downstream of the 
TetO response element promoter for tet/dox inducible expression. The pFLAG-CMV-
2_CRTC1/MAML2 (Tonon et al., 2003) construct was a gift from Frederic Kaye, the 
pLKO.1 shNS and shMAML2 (Chen et al., 2014) shRNA constructs were gifts from Lizi 
Wu, the pLMN UltramiR-E shIGF1R (ULTRA-3308043 and ULTRA-3443222) and 
shPPARGC1A (ULTRA-3197172 and ULTRA-3197171) constructs were from 
transOMICS Technologies, and the PPRE x3-TK-Luc (Kim et al., 1998) construct was a 
gift from Bruce Spiegelman. PPARγ knockdown constructs were purchased from 
Sigma-Aldrich (#SHCLNG-TRCN0000355926, #SHCLNG-TRCN0000001673, and 
#SHCLNG-TRCN0000001674). All plasmids were amplified and purified from either 
DH5a (Zymo Research #T3007) or Stbl3 (ThermoFisher Scientific #C737303) E. coli 
strains. 
sgRNA Design and Cloning 
sgRNAs targeting the PGC-1a proximal or distal promoters were designed using 
the CRISPR-ERA resource (http://crispr-era.stanford.edu/). 
The PGC-1a proximal promoter sequence was used as the query for generating 












The PGC-1a distal promoter sequence was used as the query for generating 










The pgRNA-CKB vector (Addgene #73501) (Mandegar et al., 2016) was used to 
constitutively express the target sgRNAs. sgRNAs were cloned into the pgRNA-CKB 
vector using previously published methods (Gilbert et al., 2013). Briefly, the pgRNA-
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CKB backbone was digested with Esp3I (NEB #R0734) and dephosphorylated using 
recombinant Shrimp Alkaline Phosphatase. The required sgRNAs were synthesized 
(Eton Biosciences, Inc) as oligonucleotides with Esp3I compatible overhangs (Table 5). 
Oligonucleotides were phosphorylated using T4 Polynucleotide Kinase (NEB #M0201) 
and annealed by adding 50 μM sodium chloride to the phosphorylated oligo reaction, 
denaturing the oligo mix via boiling (95 °C for 10 min), and performing an extended, 
slow cooling (~0.1°C/sec). 100 ng of the digested/dephosphorylated pgRNA-CKB 
backbone was ligated overnight with 1 μL of the 0.1 μM phosphorylated/annealed guide 
RNA using T4 DNA ligase. All sgRNA constructs were sequence verified (Eton 
Biosciences, Inc) using the primer listed in Table 5. Validation of isoform-specific 
knockdown revealed that one sgRNA construct (pSico_U6-Pan-PGC1a sgPGC) 
repressed expression of all PGC-1a isoforms, while another sgRNA construct, 
(pSico_U6-PGC1a1 sgPGC) selectively repressed expression of the major isoform 
(PGC-1a1). 
PCR and qRT-PCR 
For cell lines and fresh-frozen tissues, gene expression was measured by 
extracting RNA using a Nucleospin RNA kit (Machery-Nagel #740955) according to the 
manufacturer’s instructions. cDNA was synthesized from 1 μg of RNA using iScript 
cDNA synthesis kit (Bio-Rad #170-8890). For human tissues, RNA was extracted using 
the Maxwell 16 MDx Instrument (Promega #AS3000) and the Maxwell 16 LEV RNA 
FFPE Kit (Promega #AS1260) according to the manufacturer’s protocol (Promega 
#9FB167). cDNA was made from 1-4 μg of RNA using SuperScript IV Reverse 
Transcriptase (Invitrogen #18090050) with dNTPs (NEB #N0446S), RNase inhibitor 
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(Applied Biosystems #N808-0119), 25 μM oligo d(T)20 primer (Invitrogen #100023441) 
and 25 μM MAML2-specific reverse primer (Table 5). CRTC1/MAML2 copy number was 
determined by establishing standard curves with 100 to 1x106 copies of FLAG-
CRTC1/MAML2 plasmid. Relative gene expression of target genes was determined 
using the 2ΔΔCt method and normalized to human RPL23 expression. qRT-PCR was 
performed using FastStart Universal SYBR Green Master (Rox) Mix (Roche 
#04913850001) with 1/50 (tissue) or 1/100 (cells) volume of the cDNA iScript reaction, 
and 0.25 μM of primers (Table 4). 
Quantification and Statistical Analysis  
All statistical tests were executed using GraphPad Prism software or the 
statistical software R (version 3.1.2). Differences between variables were assessed by 
2-tailed Student’s t test, one-way ANOVA with Holm-Sidak post hoc test, or Wilcoxon 
rank sum tests, where appropriate. For proliferation assays, pairwise comparisons were 
performed by Benjamini-Hochberg analysis. Data are expressed as mean ± SEM, P 
values less than 0.05 were considered statistically significant (∗p < 0.05, ∗∗p < 0.01, 















Gene Fold Regulation Function/Process 
IGF1 112.2055 anabolism, cell proliferation, and differentiation 
FOS 49.8665 transcription, cell proliferation, and differentiation 
TIMP3 9.7136 cell adhesion 
MMP1 5.2416 cell adhesion 
TEK 4.9933 cell proliferation and differentiation 
CDKN1A 4.5948 cell cycle 
IL8 3.5554 cytokine 
THBS1 3.2043 cell adhesion 
SERPINE1 3.0105 cell adhesion 
PLAUR 2.1886 signal transduction 
 
Table 1. Cancer pathway genes induced upon CRTC1/MAML2 expression. (From Qiagen Human Cancer 




Fusion Status Cancer Cell Line Tissue BMS-754807 PPP 
C1/M2 Negative Non-MEC A-253  Salivary Gland 58.9 0.719 
          
C1/M2 Positive MEC 
UM-HMC-1  Salivary Gland 0.213 0.066 
UM-HMC-3A  Salivary Gland 0.148 0.211 
UM-HMC-3B  Salivary Gland 0.088 0.216 
NCI-H3118 Salivary Gland ND 0.4890 
 
Table 2. Calculated IC50 values of IGF-1R inhibitors on the viability of CRTC1/MAML2-positive and -negative 
cancer cell lines. Cell viability was assessed by ATPlite assay and IC50 values were calculated in GraphPad Prism 
using a non-linear curve fit (log[agonist] vs response, four parameter-variable slope). IC50 values are reported in μM 





Cancer Cell Line SR-10221 SR-2595 T0070907 
UM-HMC-1 114.5 40.1 328.1 
UM-HMC-3A 72.7 50.2 222.7 
UM-HMC-3B 148.4 78.6 329.7 
NCI-H292 76.6 ND ND 
NCI-H3118 98.5 ND ND 
 
Table 3. Calculated IC50 values of PPARγ inverse agonists on the viability of CRTC1/MAML2-positive cancer 
cell lines. Cell viability was assessed by ATPlite assay and IC50 values were calculated in GraphPad Prism using a 
non-linear curve fit (log[agonist] vs response, four parameter-variable slope). IC50 values are reported in μM and are 






Application Target Sequence (5' - 3')
Quantitative real-time PCR CRTC1-MAML2 ATG GCG ACT TCG AAC AA (forward)
GGG TCG CTT GCT GTT GGC (reverse)
IGF-1 TGT GGA GAC AGG GGC TTT TA (forward)
ATC CAC GAT GCC TGT CTG A (reverse)
IGF-1 Exon 1 GAT AGA GCC TGC GCA ATG GAA (forward)
GAG ATG GGA GAT GTT GAG AGC A (reverse)
IGF-1R AAA AAC CTT CGC CTC ATC CT (forward)
TGG TTG TCG AGG ACG TAG AA (reverse)
NR4A2 TGA AGA GAG ACG CGG AGA AC (forward)
AAA GCA ATG GGG AGT CCA G (reverse)
PGC-1⍺1 ATG GAG TGA CAT CGA GTG TGC T (forward)
GAG TCC ACC CAG AAA GCT GT (reverse)
PGC-1⍺2 AGT CCA CCC AGA AAG CTG TCT (forward)
ATG AAT GAC ACA CAT GTT GGG (reverse)
PGC-1⍺3 CTG CAC CTA GGA GGC TTT ATG C (forward)
CAA TCC ACC CAG AAA GCT GTC T (reverse)
PGC-1⍺4 TCA CAC CAA ACC CAC AGA GA (forward)
CTG GAA GAT ATG GCA CAT (reverse)
PGK1 TTG ACC GAA TCA CCG ACC TC (forward)
ACC CGC TTC CCT TTA ACG TC (reverse)
PKM2 CGT CTG AAC TTC TCT CAT GGA A (forward)
ATG GGG TCA GAA GCA AAG C (reverse)
RPL23 TGA TGG CCA CAG TCA AGA AA (forward)
ACA CGC CAT CTT TTC TAC GG (reverse)






Application Target Sequence (5' - 3')
Mycoplasma detection Mycoplasma TGC ACC ATC TGT CAC TCT GTT AAC CTC (forward)
GGG AGC AAA CAG GAT TAG ATA CCC T (reverse)
MAML2 cDNA synthesis MAML2 CTC TGA GGG ACT GAA GGG AT (reverse)
Chromatin IP GAPDH CCT TCT TGC CTT GCT CTT GCT AC (forward)
GCC TGC CTG GTG ATA ATC TTT G (reverse)
NR4A2 GTT GCA CCC TCC CCA CAT G (forward)
GGC CGC CAA TGT GCC TTT GTT TAT (reverse)
Distal PGC-1⍺ CAG TCA GTT ATG GGC ATG (forward)
CAC TCA CAA CAA GGG CTT CG (reverse)
IGF-1 CCA CTC CTG CCA GAA CGC (forward)
GGG AGG AGA AAT CCT CTC AC (reverse)
sgRNA Cloning sgPGC-1⍺1 TTG GAC TGG GGA CTG TAG TAA GAC (forward)
AAA CGT CTT ACT ACA GTC CCC AGT (reverse)
sgPGC-1⍺ (Total) TTG GCC GGG ATA AAG TGT CAT CAT (forward)
AAA CAT GAT GAC ACT TTA TCC CGG (reverse)
Sequence verification GAG ATC CAG TTT GGT TAG TAC CGG G
Table 5. Primers used for detection of mycoplasma in cell cultures, MAML2 gene-specific cDNA synthesis, 
chromatin IP, and cloning and sequence verification of sgRNA constructs. 
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Figure 1. Salivary gland structure. The salivary glands consist of a branched ductal structure formed through a 
process known as branching morphogenesis. Saliva is produced by the acinar cells, which cluster in groups called 





Figure 2. Salivary MEC is characterized by a t(11;19)(q14-21;p12-13) translocation. (A) The t(11;19) 
translocation fuses the first exon of CRTC1 with exons 2-18 of MAML2, creating the CRTC1/MAML2 fusion product. 
This fusion retains the CREB-binding domain from CRTC1 and the transcriptional activation domain from MAML2. 
CBD: CREB-binding domain; NES: nuclear export signal; NBD: Notch-binding domain; TAD: transcriptional activation 
domain. Schematic created in BioRender. (B-C) The ZytoLight MAML2 Dual Color Break Apart Probe can be used to 
detect MAML2 rearrangements. The red and green fluorescent probes bind to the 3’ and 5’ ends of the MAML2 gene, 
respectively. In cells with no MAML2 rearrangement (B), the two probes colocalize, and in cells with a MAML2 
rearrangement (C), individual green and red probes can be detected. (D-E) Fluorescent in-situ hybridization in 
CRTC1/MAML2-negative A253 cells (D; yellow arrowheads indicate probe colocalization) and CRTC1/MAML2-





Figure 3. CRTC1/MAML2 is expressed in >50% of human MEC samples. qRT-PCR analysis of CRTC1/MAML2 
(C1/M2) expression in human salivary MEC tumor samples. C1/M2 copy number per 10 ng input RNA was calculated 
based on a standard curve. Samples with <500 C1/M2 transcripts per 10 ng RNA were classified as fusion-negative 
(grey bars), while those with ≥500 C1/M2 transcripts per 10 ng RNA were classified as fusion-positive (blue bars). 






Figure 4. Normal salivary glands, CRTC1/MAML2-positive MEC, and CRTC1/MAML2-negative MEC tumors are 
characterized by distinct gene signatures. Heat map showing unsupervised clustering of the top 1500 most 
variable genes between MEC and normal salivary gland samples. Normal (e.g. N #1, N #2) and tumor (e.g. Case #1, 
Case #7) samples are indicated at the top of the heat map in black and green, respectively. CRTC1/MAML2 fusion 






Figure 5. An IGF-1 related gene signature is characteristic of fusion-positive MEC. (A) Heat map of IGF1-
related DEGs between fusion-positive MEC and normal salivary gland samples. Normal (e.g. N #1, N #2) and tumor 
(e.g. Case #1, Case #7) samples are indicated at the top of the heat map in black and green, respectively. 
CRTC1/MAML2 status is indicated in grey (negative) and blue (positive). Hierarchical clustering was performed using 
ComplexHeatmap R package version 2.0.0. (B) Violin plot highlighting the significance of IGF-1 pathway-related 
genes within our curated Musicant_MEC_CRTC1-MAML2_IGF1 gene set between fusion-positive MEC and normal 






Figure 6. Curated Musicant_MEC_CRTC1-MAML2_IGF1 gene set distinguishes CRTC1/MAML2-positive MEC. 
Gene set enrichment plots for genes in the GSEA Molecular Signatures Database (MSigDB) GNF2_IGF1 dataset (A) 
and our curated Musicant_MEC_CRTC1- MAML2_IGF1 gene set (B) in fusion-positive MEC and normal salivary 






Figure 7. CRTC1/MAML2 and IGF-1 transcript levels are correlated in human MEC tumor samples. Comparison 
of CRTC1/MAML2 (C1/M2) and IGF-1 CT values in qRT-PCR data from human CRTC1/MAML2-positive MEC tumor 
(blue) and normal salivary gland (grey) samples. The fitted regression line demonstrates the correlation between the 
expression levels of the two genes (r2 = 0.7251, p < 0.0001). 95% confidence intervals are indicated by curved lines 






Figure 8. CRTC1/MAML2 and IGF-1 transcript levels are correlated in MEC cell lines. (A, B) qRT-PCR analysis 
of CRTC1/MAML2 (C1/M2) (A) and IGF-1 (B) expression in MEC cell lines and control epidermoid carcinoma cell 
lines. Cell lines are listed along the x-axis, with CRTC1/MAML2 status indicated below in grey (negative) or red 
(positive). C1/M2 copy number per 10 ng input RNA was calculated based on a standard curve. Relative IGF-1 fold 
expression is shown normalized to RPL23 mRNA levels. Data is presented as the mean ± SEM (n = 3). (C) 
Comparison of C1/M2 and IGF-1 CT values in qRT-PCR data from cell lines. CRTC1/MAML2-negative cell lines are 
indicated in grey and CRTC1/MAML2-positive cell lines are indicated in red. The fitted regression (solid) line 
demonstrates that the expression levels of the two genes are correlated (r2 = 0.8664, p = 0.0008). 95% confidence 






Figure 9. CRTC1/MAML2-positive xenografts display increased IGF-1 expression. Histologic and 
immunohistochemical analysis of CRTC1/MAML2-positive (HMC1, HMC3A, and HMC3B) and CRTC1/MAML2-
negative (A253) xenografts. Representative xenograft sections were formalin fixed, embedded, and H&E stained (top; 
magnification: 200x; scale bar: 100 μm), revealing epidermoid cells in CRTC1/MAML2-negative xenografts and 
epidermoid, mucus, and intermediate cells in the CRTC1/MAML2-positive xenografts. Mucicarmine staining (middle; 
magnification: 400x; scale bar: 100 μm) revealed mucus cells (indicated by yellow arrows) in CRTC1/MAML2-positive 
xenografts. IHC staining for IGF-1 (bottom; magnification: 200x; scale bar: 100 μm) demonstrated that IGF- 1 







Figure 10. A focused small molecule drug screen identifies sensitivity of CRTC1/MAML2-positive tumor cells 
to compounds targeting IGF-1R. (A) Drug screen performed in five CRTC1/MAML2-positive MEC cell lines and one 
CRTC1/MAML2-negative epidermoid carcinoma cell line. 176 inhibitors were tested, in duplicate, across all cell lines 
at six concentrations ranging from 10 nM to 10 μM. DMSO (1%) and Bortezomib (1 μM) were used as negative and 
positive controls, respectively, on each plate. Several IGF-1R and EGFR inhibitors emerged as top hits, inducing cell 
death in CRTC1/MAML2-positive cell lines at >5 standard deviations above baseline (DMSO). (B) Analysis of drug 
screen robustness based on a Z’-factor analysis. Data points in red indicate viability of cells treated with positive 
control (1 μM Bortezomib; 100% cell death) and data points in blue indicate viability of cells treated with negative 
control (DMSO; 0% cell death). Cell lines are listed along the x-axis, with CRTC1/MAML2 status indicated below in 
grey (negative) or red (positive). Z’-factor >0.75 confirms a robust dynamic range of drug effects indicating good drug 
screen reliability. (C) Relative cell death induced by drug screen inhibitors. IGF-1R and EGFR inhibitors more 
effectively induced cell death in CRTC1/MAML2-positive MEC cells compared with CRTC1/MAML2-negative 






Figure 11. Sensitivity of three CRTC1/MAML2-positive cell lines to IGF-1R inhibition. Representative dose 
response curves showing viability of three CRTC1/MAML2-positive cell lines (HMC1, HMC3A, and HMC3B) treated 
with increasing concentrations of IGF-1R inhibitors (BMS-754807 and PPP). IC50 values were calculated using a non-
linear curve fit (log[agonist] versus response, four parameter-variable slope) in GraphPad Prism. Experiment was 
performed in biologic triplicate (n = 3 technical replicates for each experiment), with one representative experiment 







Figure 12. Validation of IGF-1R inhibition and shRNA-mediated knockdown. (A) Representative western blot 
showing expression of total and phosphorylated (Tyr1135) IGF-1R protein in HMC1 cells treated with BMS-754807 or 
PPP. (B) Quantification of phosphorylated (Tyr1135) IGF- 1R protein levels following IGF-1R inhibitor treatment. 
Band intensities were normalized to β-actin and to total IGF-1R and are shown as the fold change in phosphorylated 
band intensity relative to the untreated condition. Data are presented as the mean ± SEM (n = 3 biological replicates; 
one-way ANOVA with Holm-Sidak post hoc test; ns = not significant, *p ≤ 0.05). (C) qRT-PCR analysis of IGF-1R 
mRNA levels in cells transduced with lentiviruses expressing either a non-specific shRNA (shNS) or two different 
shRNAs targeting IGF-1R (shIGF-1R_#1 and shIGF-1R_#2). Relative fold expression is shown normalized to RPL23 
mRNA levels. Data are presented as the mean ± SEM (n = 3; Student’s t-test; **p ≤ 0.01). (D) Representative 
western blot demonstrating relative knockdown of IGF-1Rβ protein levels with shIGF1R_#1 and shIGF1R_#2 relative 
to control shRNA (shNS). (E) Quantification of IGF-1R protein levels following IGF-1R knockdown. Band intensities 
were normalized to β-actin and are shown as the fold change in band intensity relative to the shNS condition. Data 






Figure 13. IGF-1R inhibition blocks MEC cell growth and survival. (A) Cell proliferation assay showing relative 
confluency of HMC3A cells treated with DMSO or PPP (see Table 2 for IC50 values). GC50 values for each condition 
are shown in hours and indicate the time required for cells to reach 50% confluency. ND: not determined. Experiment 
was performed in biologic triplicate (n = 4 technical replicates per experiment) with one representative experiment 
shown (mean ± SEM; Benjamini-Hochberg pairwise comparisons; **p ≤ 0.01, ***p ≤ 0.001). Data collected using 
InCucyte live cell imager. (B) Number of colonies formed by HMC3A cells treated with DMSO or PPP. A colony is 
defined as a cluster of ≥50 cells. Representative images of wells treated with DMSO and PPP (IC50 concentration; 
see Table 2 for IC50 values) are shown to the left. Data are presented as the mean ± SEM (n = 3 biological replicates; 
Student’s t-test; ****p ≤ 0.0001). (C) Number of colonies formed by HMC1 (left), HMC3A (center), and HMC3B (right) 
cells treated with DMSO or BMS-754807 (see Table 2 for IC50 values). A colony is defined as a cluster of ≥50 cells. 
Data are presented as the mean ± SEM (n = 3 biological replicates; Student’s t-test; *p ≤ 0.05, **p ≤ 0.01). (D) Left, 
Representative images of HMC3A tumorspheres on day one (top) and seven days post treatment with DMSO 
(vehicle control) or increasing concentrations of PPP. Right, Tumorsphere formation in HMC3A cells treated with 
DMSO or increasing concentrations of PPP. Percent change in tumorsphere area is calculated as 
[TumorAreaDayX]/[TumorAreaDay1]*100. >50 individual tumorspheres per condition were tracked for each individual 
experiment. Data are presented as the mean ± SEM (n = 3 biological replicates; Student’s t-test; ****p ≤ 0.0001). (E) 
Apoptosis levels (measured as % cleaved Caspase 3/7) in HMC3A cells treated with DMSO or PPP. Data was 
collected via flow cytometry and normalized to a non-stained control for each condition. Data are presented as the 






Figure 14. CRTC1/MAML2 induces IGF-1 expression. (A, B) qRT-PCR analysis of CRTC1/MAML2 (C1/M2) (A) 
and IGF-1 (B) mRNA levels in HEK293-CMVTetRTetOC1/M2 cells treated with and without 1 μg/mL doxycycline. 
Relative fold expression is shown normalized to RPL23 mRNA levels. Data are presented as the mean ± SEM (n = 3; 
Student’s t-test; ***p < 0.001, ****p < 0.0001). (C) AlphaLISA-based analysis of secreted IGF-1 in media from 
HEK293-CMVTetRTetOC1/M2 cells with and without 1 μg/mL doxycycline treatment. Data are presented as the mean ± 
SEM (n = 3; Student’s t-test; **p = 0.003). (D) Western blotting analysis of IGF-1 and tubulin protein expression levels 
in HEK293-CMVTetRTetOC1/M2 cells treated with and without 1 μg/mL doxycycline. (E) Left, Schematic depicting the 
AlphaLISA assay. Donor and acceptor beads each carry an antibody that detects the analyte of interest. Donor beads 
can be excited by light at 680 nm and can then convert molecular oxygen to its excited state. Acceptor beads can 
utilize the excited oxygen molecule to emit light at 615 nm. The transfer of this excited molecular oxygen can only 
occur when donor and acceptor beads are brought into close proximity through mutual binding of the analyte. Thus, 
quantification of light at 615 nm allows for indirect quantification of analyte levels. Right, Standard curve showing the 





Figure 15. CRTC1/MAML2 induces expression of the PGC-1α4 splice variant. (A) Chromatin 
immunoprecipitation analysis of Flag-CRTC1/MAML2 (Flag-C1/M2) promoter occupancy in HEK293-
CMVTetRTetOC1/M2 cells. Data are expressed as promoter occupancy in doxycycline-treated cells normalized to 
promoter occupancy in vehicle-treated cells. GAPDH and NR4A2 promoters were used as negative and positive 
controls, respectively. Data are presented as the mean ± SEM (n = 3; Student’s t-test; ***p < 0.001, **p < 0.01). (B) 
Luciferase assay measuring activation of the distal and proximal PGC-1α promoters in HEK293-CMVTetRTetOC1/M2 
cells with and without 1 μg/mL doxycycline treatment. Data are presented as the mean ± SEM (n = 3; Student’s t-test; 
***p < 0.001). (C) qRT-PCR analysis of PGC-1α4 mRNA expression in HMC3A cells with and without shRNA-
mediated CRTC1/MAML2 knockdown. Relative fold expression is shown normalized to RPL23 mRNA levels and to 
mock transduced condition. shNS: non-specific shRNA. shMAML2_#1 and shMAML2_#3: shRNAs targeting 
CRTC1/MAML2 and MAML2. Data are presented as the mean ± SEM (n = 3; Student’s t-test; **p < 0.01). (D) qRT- 
PCR analysis of CRTC1/MAML2 (C1/M2) (left) and NR4A2 (right) mRNA levels in HMC3A cells transduced with a 
non-specific shRNA (shNS) or two different shRNAs targeting CRTC1/MAML2 (shMAML2_#1 and shMAML2_#3). 
Relative fold expression is shown normalized to RPL23 mRNA levels. Data are presented as the mean ± SEM (n = 3; 
Student’s t-test; ns = not significant, *p ≤ 0.05, **p ≤ 0.01). (E) qRT- PCR analysis of PGC-1α4 mRNA levels in 
HMC3A-PGKTetOn3GTRE3GSdnCREB cells treated with and without 1 μg/mL doxycycline. Relative fold expression is 







Figure 16. The PGC-1α4 variant is highly expressed in CRTC1/MAML2-positive MEC. (A) Temporal analysis of 
CRTC1/MAML2 (C1/M2), PGC-1α4, and IGF-1 expression kinetics in HEK293-CMVTetRTetOC1/M2 cells treated with 1 
μg/mL doxycycline for 0-48 hours. C1/M2 and PGC-1α4 expression is indicated on the left y-axis, while IGF-1 
expression is indicated on the right y-axis. Relative fold expression is shown normalized to RPL23 mRNA levels. Data 
are presented as the mean ± SEM (n = 3; Student’s t-test; ***p < 0.001). (B) qRT-PCR analysis of PGC-1α4 
expression in CRTC1/MAML2-positive and -negative cell lines. Cell lines are listed along the x-axis, with 
CRTC1/MAML2 status indicated below in grey (negative) or red (positive). Relative fold expression is shown 
normalized to RPL23 mRNA levels. Data are presented as the mean ± SEM (n = 3). (C) qRT-PCR analysis of PGC-
1α1, PGC-1α2, PGC-1α3, and PGC-1α4 mRNA levels in CRTC1/MAML2-positive and CRTC1/MAML2-negative cell 
lines. Cell lines are listed along the x-axis, with CRTC1/MAML2 status indicated below. Relative fold expression is 






Figure 17. CRISPRi-based knockdowns confirm that IGF-1 is regulated by a specific PGC-1α isoform. (A) 
qRT-PCR analysis of IGF-1 mRNA levels in HMC3A cells transduced with unique gRNAs targeting the PGC-1a1 
isoform only (PGC-1a1 sgRNA) or all PGC-1a isoforms (Pan-PGC-1a sgRNA). Relative fold expression is shown 
normalized to RPL23 mRNA levels. Data are presented as the mean ± SEM (n = 3; Student’s t-test; ***p < 0.001). (B) 
qRT-PCR analysis of PGC-1α1 and PGC-1α4 mRNA levels in HMC3A cells transduced with unique gRNAs targeting 
the canonical PGC-1α1 transcript only or all PGC-1α isoforms. Relative fold expression is shown normalized to 






Figure 18. Overexpression of PGC-1α4 drives IGF-1 transcription. (A) qRT-PCR analysis of PGC-1α4 mRNA 
levels in HEK293- PGKTetOn3GTRE3GSPGC-1α4 cells treated with increasing concentrations of doxycycline for 24 hr. 
Relative fold expression is shown normalized to RPL23 mRNA levels. Data are presented as the mean ± SEM (n = 3 
biological replicates with 3 technical replicates each; Student’s t-test; ****p < 0.0001). (B) Western blot showing Flag-
PGC-1α4 and tubulin protein expression levels in HEK293-PGKTetOn3GTRE3GSPGC-1α4 cells treated with increasing 
concentrations of doxycycline for 24 hr. Blot is representative of 3 independent biological replicates. (C) qRT-PCR 
analysis of PGC-1α4 and IGF-1 mRNA expression in HEK293-PGKTetOn3GTRE3GSPGC-1α4 cells treated with 1 μg/mL 
doxycycline for 0-48 hours. Relative fold expression is shown normalized to RPL23 mRNA levels. Data are presented 






Figure 19. Knockdown of key signaling components inhibits proliferation of MEC cells. Cell proliferation 
assays showing relative confluency of HMC3A cells with and without shRNA-mediated knockdown of PGC-1α (left), 
IGF-1R (center), or CRTC1/MAML2 (C1/M2) (right). Time to 50% confluence is shown by dashed lines. shNS = non-
specific shRNA; shPGC-1α_#1 and _#2 = shRNAs targeting PGC-1α; shIGF-1R_#1 and _#2 = shRNAs targeting 
IGF-1R; shMAML2_#3 = shRNA targeting CRTC1/MAML2 and MAML2. Experiment was performed in biologic 
triplicate (n = 3 technical replicates per experiment) with one representative experiment shown (mean ± SEM; 







Figure 20. CRTC1/MAML2 overexpression activates IGF-1 and PPARγ-response element luciferase reporters. 
(A) Schematic of the human IGF-1 gene locus, highlighting the P2 promoter (located upstream of the second exon) 
as well as several PPARγ (PPARG) binding motifs located within this promoter region. (B, C) Light output generated 
by an IGF-1 P2 promoter-driven luciferase reporter (B) or a PPARγ-response element (PPRE)-driven luciferase 
reporter (C) in HEK293-CMVTetRTetOC1/M2 cells treated with and without 1 μg/mL doxycycline treatment. Data are 






Figure 21. IGF-1 activation is dependent on PPARγ-mediated signaling. PPARγ-response element (PPRE)-
driven (A, C) and IGF-1 promoter-driven (B, D) luciferase reporter assay showing activation and repression of basal 
activity of endogenously expressed PPARγ in doxycycline-treated HEK293-CMVTetRTetOC1/M2 cells. Cells were 
treated with increasing concentrations of the PPARγ agonist GW1929 (A, B) or the PPARγ inverse agonist 
SR10221(C, D) for 24 hr prior to measuring luciferase activity. IC50 values were calculated using a non-linear curve fit 
(log[agonist] vs response, four parameter-variable slope) in GraphPad Prism. Experiment was performed in biologic 






Figure 22. PPARγ knockdown inhibits IGF-1 expression and induces apoptosis in MEC cells. (A) 
Representative western blot demonstrating knockdown of PPARγ protein levels using three separate PPARγ-targeted 
shRNAs (#1, #2, and #3) relative to a control shRNA (shNS). IGF-1 levels were also detected and were observed to 
decrease upon PPARγ knockdown. (B) Quantification of PPARγ and IGF-1 protein levels in PPARγ knockdown 
samples. Band intensities were normalized to β-actin and are shown as the fold change in band intensity relative to 
the shNS-treated condition. Data are presented as the mean ± SEM (n = 3 biological replicates; Student’s t-test; **p ≤ 
0.01, ***p ≤ 0.001, ****p ≤ 0.0001). (C) Apoptosis levels (measured as % cleaved Caspase 3/7) in HMC1 and HMC3A 
cells transduced with three separate PPARγ-targeted shRNAs (#1, #2, and #3) or a control shRNA (shNS). 48 hr 
after transduction, data was collected via flow cytometry and normalized to a non-stained control for each condition. 




Figure 23. PPARγ inverse agonists inhibit IGF-1 expression. (A) Dose response curves showing viability of three 
CRTC1/MAML2-positive cell lines (HMC1, HMC3A, and HMC3B) treated with increasing concentrations of PPARγ 
inverse agonists (SR10221, SR2595, and T0070907). IC50 values were calculated using a non-linear curve fit 
(log[agonist] vs response, four parameter-variable slope) in GraphPad Prism. Experiment was performed in biologic 
triplicate (n = 3 technical replicates for each experiment), with one representative experiment shown. See Table 3 for 
IC50 values. (B) qRT- PCR analysis of IGF-1, PGK1, and PKM2 expression in HMC3A cells treated with vehicle 
(DMSO) or SR2595. Relative fold expression is shown normalized to RPL23 mRNA levels. Data are presented as the 
mean ± SEM (n = 3; Student’s t-test; ***p ≤ 0.001). (C) Representative western blot showing expression of IGF-1 
protein in HMC3A cells treated with increasing concentrations of SR2595. (D) Quantification of IGF-1 protein levels in 
SR2595-treated HMC3A cells. Band intensities were normalized to β-actin and are shown as the fold change in band 
intensity relative to the vehicle-treated condition. Data are presented as the mean ± SEM (n = 3 biological replicates; 





Figure 24. PPARγ inverse agonists suppress MEC cell growth, proliferation, and survival. (A) Cell proliferation 
assay showing relative confluency of HMC3A cells treated with DMSO or SR10221. Experiment was performed in 
biologic triplicate (n = 4 technical replicates per experiment) with one representative experiment shown (mean ± SEM; 
Benjamini-Hochberg pairwise comparisons; ***p ≤ 0.001). Data collected using IncuCyte live cell imager. (B) Colony 
formation in HMC1 cells treated with DMSO or SR10221 (see Table 3 for IC50 values). A colony is defined as a 
cluster of ≥50 cells. Data are presented as the mean ± SEM (n = 3; Student’s t-test; ***p ≤ 0.001). (C) Tumorsphere 
formation in HMC3A cells treated with DMSO or SR10221. Percent change in tumorsphere area is calculated as 
[TumorAreaDayX]/[TumorAreaDay1]*100. >50 individual tumorspheres per condition were tracked for each individual 
experiment. Data are presented as the mean ± SEM (n = 3 biological replicates; Student’s t-test; **p ≤ 0.01, ***p ≤ 
0.001). (D) Apoptosis levels (measured as % cleaved Caspase 3/7) in HMC3A cells treated with DMSO or SR10221. 
Data was collected via flow cytometry and normalized to a non-stained control for each condition. Data are presented 




Figure 25. PPARγ inverse agonists suppress tumor growth in a xenograft model of salivary MEC. (A) Growth 
of HMC3A xenograft tumors over time during treatment with either SR10221 or a vehicle control. Tumor xenograft 
volume was quantified by caliper measurements obtained on the indicated days following initiation of drug 
administration. Decreased tumor volume in the SR10221 cohort correlates directly with suppression of tumor growth 
in vivo (n = 4, mean ± SEM; Student’s t-test; ****p ≤ 0.0001). (B) Weight of resected vehicle- and SR10221-treated 
HMC3A tumor xenografts at study endpoint (n = 4, mean ± SEM; Student’s t-test; **p ≤ 0.01). (C) Representative in 
vivo bioluminescent images obtained at endpoint of Nu/Nu mice bearing subcutaneous HMC3A tumor xenografts and 
treated with either SR2595 or a vehicle control. Images were captured with an open filter and an acquisition time of 5 
min (binning = 2; FOV = 25; Fstop = 2; object height = 1.5). (D) Weights of Nu/Nu mice bearing subcutaneous 
HMC3A xenograft tumors and treated with SR2595 or a vehicle control for up to 24 days (n = 4, mean ± SEM). (E) 
Comparison of HMC3A xenograft tumor growth following treatment with either SR2595 or vehicle control. 
Bioluminescence imaging (BLI) signals from tumor xenografts were quantified by region of interest (ROI) analysis of 
images obtained at endpoint (day 24 following initiation of drug administration). Decreased BLI signal in the SR2595 
cohort correlates directly with suppression of tumor growth in vivo (n = 4, mean ± SEM; Student’s t-test; **p ≤ 0.01). 
(F, G) Volume (F) and weight (G) of resected vehicle- and SR2595-treated HMC3A xenograft tumors at study 





Figure 26. Schematic of the CRTC1/MAML2 – PGC-1α4 – IGF-1 signaling pathway.  CRTC1/MAML2 acts as a 
rogue coactivator of the transcription factor CREB. In MEC, this interaction drives the production of a minor PGC-1α 
splice variant, PGC-1α4. PGC-1α4 in turn can coactivate the transcription factor PPARγ to stimulate production of the 
IGF-1 growth hormone. Secreted IGF-1 ligand can bind to cell surface IGF-1R receptors and stimulate key signaling 
pathways driving survival, growth, and proliferation, all of which are key tumor-supportive functions. Our study 
demonstrated that this CRTC1/MAML2 mediated signaling cascade can be inhibited using either PPARγ inverse 

















Figure 27. Cells targeted by Cre promoters used in transgenic lines. Dcpp1 is expressed in the intercalated duct 
cells and serous demilune cells. Mist1 is expressed in acinar cells. Krt14 is expressed in excretory, striated, and 







Figure 28. Bioluminescent imaging demonstrates transgene expression patterns in LumiFluor-positive 
animals. Representative in vivo bioluminescent images of control (LumiFluor-negative), K14Cre-LumiFluor, MistCre-
LumiFluor, and DcppCre-LumiFluor animals obtained 3- and 9-months post tamoxifen administration. Images were 






Figure 29. CRTC1/MAML2 is expressed in salivary gland tissue of DcppCre-C1/M2, MistCre-C1/M2, and K14Cre-
C1/M2 transgenic mice. qRT-PCR analysis of CRTC1/MAML2 expression in control (CRTC1/MAML2-negative), 
DcppCre-C1/M2, MistCre-C1/M2, and K14Cre-C1/M2 animals 4 months post tamoxifen administration. CRTC1/MAML2 
copy number per 10 ng input RNA was calculated based on a standard curve. Data is presented as the mean ± SEM 






Figure 30. Ductal expression of CRTC1/MAML2 drives a dysplastic and hyperproliferative phenotype. 
Representative H&E images from control (CRTC1/MAML2-negative), MistCre-C1/M2, DcppCre-C1/M2, and K14Cre-
C1/M2 salivary glands ~6 months post tamoxifen administration. SMG: submandibular gland. SLG: sublingual gland. 





Figure 31. CRTC1/MAML2 overexpression alone fails to induce MEC formation independent of Cre driver. 
Disease (MEC)-free survival (DSS) and overall survival (OS) of control (CRTC1/MAML2-negative), MistCre-C1/M2, 





Figure 32. Generation of Ductal-PTightC1/M2PGKLumiFluor stable cells. (A) Schematic of engineered cell lines. In the 
Ductal-PTighttdTOPGKLumiFluor cells, the TdTomato gene is under the control of a doxycycline-inducible PTight promoter, 
while the GpNLuc (LumiFluor) reporter is driven by a constitutively active PGK promoter. In the Ductal-
PTightC1/M2PGKLumiFluor cells, CRTC1/MAML2 is under the control of a doxycycline-inducible PTight promoter, while the 
LumiFluor reporter is driven by a constitutively active PGK promoter. (B) Flow cytometric analysis of GpNLuc and 
TdTomato reporter expression in parental ductal cells (blue trace), uninduced Ductal-PTighttdTOPGKLumiFluor cells (green 
trace), and doxycycline induced Ductal-PTighttdTOPGKLumiFluor cells. (C) Quantification of GpNLuc (green line) and 
TdTomato (red line) expression in parental ductal cells (DC) and Ductal-PTighttdTOPGKLumiFluor cells treated with 0-2 
μg/mL doxycycline. Data was collected via flow cytometry and was normalized to the background fluorescence from 
parental ductal cells (0% induction) and to the highest fluorescence achieved in induced Ductal-PTighttdTOPGKLumiFluor 
cells (100% induction). (D) qRT-PCR (bar graph) and western blot (inset) analysis of CRTC1/MAML2 (C1/M2) 
expression in Ductal-PTighttdTOPGKLumiFluor cells with and without 0.5 μg/mL doxycycline treatment. For qRT-PCR, 
C1/M2 copy number per 10 ng input RNA was calculated based on a standard curve. (E) Luciferase assay measuring 






Figure 33. CRTC1/MAML2-positive human MEC tumors display increased p53 dysregulation. Box and whisker 
plots showing correlation of high-grade MEC, low-grade MEC, and normal salivary gland samples with a breast 
cancer-derived p53 gene signature (Troester et al., 2006). CRTC1/MAML2-positive and -negative samples are shown 





Figure 34. Salivary MEC tumors arise in K14Cre-C1/M2-p53f/f mice four months after tamoxifen administration. 
(A) Disease (MEC)-specific survival in K14Cre-C1/M2-p53f/f animals compared with all other animals in this study 
(CRTC1/MAML2-positive and -negative, p53 wild-type, p53f/+, p16 wild-type, p16f/+, and p16f/f). (B-C) Representative 
tumor images from K14Cre-C1/M2-p53f/f mice. (D) Representative H&E-stained murine MEC tumor from a K14Cre-
C1/M2-p53f/f mouse. Colored arrows indicate mucous (white), epidermoid (black), and intermediate (blue) cells. Scale 





Figure 35. MSigDB pathways dysregulated in MEC GEMM tumors. Heat map showing significantly differentially 
expressed gene lists (p < 0.05) within the Molecular Signatures Database (MSigDB). Tumor and normal samples are 







Figure 36. Musicant_MEC_CRTC1-MAML2_IGF1 gene set distinguishes MEC GEMM tumors. Heat map 
showing differential expression of genes in the curated Musicant_MEC_CRTC1-MAML2_IGF1 gene set in MEC 
GEMM tumors. Tumor gene expression was compared to gene expression in matched normal submandibular gland 





Figure 37. MEC GEMM tumors mimic both low- and high-grade human MEC. (A) Heat map of significant DEGs 
between low- and high-grade MEC and normal salivary gland samples. Low- and high-grade MEC are indicated at 
the top in red and blue, respectively. Normal samples are indicated in green. Hierarchical clustering was performed 
using ComplexHeatmap R package version 2.0.0. (B) Gene expression data from MEC GEMM tumors were 
compared to gene expression data from low, intermediate, and high grade CRTC1/MAML2-positive human MEC 
tumors. Correlation between each GEMM sample was calculated such that a score of 1 indicates perfect correlation. 
Two MEC GEMM tumor samples (GEMMSEQ005_C1 and GEMSEQ008_C4) displayed a strong correlation with 
gene expression profiles seen in high grade CRTC1/MAML2-positive human MEC tumors. The remaining MEC 
GEMM tumor sample (GEMMSEQ006_C2) correlated best with the gene expression profiles of low grade 





Figure 38. Krt14-driven oncogene expression results in significant oral lesion formation. (A) Significant oral 
lesions are formed by Krt14-driven gene expression. (B-C) Representative H&E images from the oral tissue shown in 








Figure 39. Direct injection of adenoviral Cre results in temporary LumiFluor signal. (A-C) Representative in 
vivo bioluminescent images of LSL-LumiFluor animals 10 days (A), 27 days (B), and 60 days (C) after being injected 
trans-dermally with either Ad-GFP (control, left) or Ad-Cre (middle and right). Images were captured with an open 
filter and an acquisition time of 5 min (binning = 2; FOV = 25; Fstop = 2; object height = 1.5). (D) Bioluminescence 
imaging (BLI) signals were quantified by region of interest (ROI) analysis at the indicated time points following 
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